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ABSTRACT 
Chlamydia trachomatis is the causative agent of the most prevalent sexually 
transmitted bacterial infection in the United States. Antibiotic therapy is currently 
effective in treating Chlamydia infection; however, the vast majority of infected 
individuals are asymptomatic. In women, untreated cases of Chlamydia infection can lead 
to serious reproductive health consequences. In the current absence of a safe and effective 
vaccine, my study focused on development of a vaginally-delivered topical microbicide 
as an alternative strategy for prevention of Chlamydia. 
The paucity of a well-established method suitable for large-scale analysis of 
in vitro Chlamydia infection is a major limitation in the development of novel 
anti-Chlamydia compounds. In my effort to identify compounds that can be considered as 
microbicide candidates, I developed two automated methods for enumeration of 
Chlamydia that are amenable to a large-scale study. The automated immunofluorescence 
image-based assay uses computational analysis of microscopic images, and allows 
automated phenotypic characterization and classification of Chlamydia-infected host 
cells. The second method utilizes a host cell viability assay, and offers a facile approach 
with reduced liquid-handling requirements, as well as the ability to simultaneously assess 
anti-Chlamydia and cytotoxic properties of compounds. Both methods yielded 
enumeration of Chlamydia infection that is comparable to the conventional manual 
microscopy while drastically reducing the time requirements for analysis.  
Using the automated image-based method, I performed a compound screen to test 
in vitro susceptibility of C. trachomatis to small subsets of compounds for the two main 
components of microbicides; excipient and active ingredient. Excipient candidates were 
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cellulose ether polymers, commonly used in vaginal gels and have pharmaceutical 
properties that favor their use in the preparation of controlled-release formulations for 
long-term administration of vaginal microbicide. Candidate active ingredients were 
analogues of an antibiotic polymyxin B (PMB) rationally designed to target lipid A 
portion of Gram-negative lipopolysaccharide (LPS). A wide range of anti-chlamydial 
activity was observed among cellulose ether polymers, and 14 out of 18 PMB analogues 
exhibited greater than 60% inhibition of Chlamydia growth.  
Additionally, I was interested in studying the biological role of chlamydial 
lipooligosaccharide (LOS), using small molecule DS-96 targeting lipid A as a chemical 
probe. DS-96 effectively blocked chlamydial attachment and entry steps, suggesting that 
chlamydial LOS plays a role in these steps. These data were supported by the observation 
that a high level of inhibition by DS-96 was maintained through centrifugation, which is 
known to enhance Chlamydia infection but thought to override the attachment and entry 
mechanisms. Together, these data demonstrated that targeting chlamydial LOS is 
effective in blocking Chlamydia infection prior to the bacterial entry, and therefore, has a 
high potential to be a suitable approach for prevention of Chlamydia infection. 
Furthermore, utilizing DS-96 as chemical tool, my study expanded upon the current 
understanding of the biological significance of chlamydial LOS. 
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Chapter I.  
Introduction 
 
Public Health Impact of Chlamydia 
The phylum Chlamydiae represents a unique group of obligate intracellular 
bacteria, which are estimated to have been diverged from the planctobacterial phylum 
approximately two billion years ago, whereas the pathogenic species diverged from 
environmental Chlamydiae some 700 million years ago [1, 2]. The members of the family 
Chlamydiaceae infect a diverse array of hosts including birds, reptiles, amphibians, and 
mammals, causing acute and chronic diseases in humans and animals. [3] The earliest 
description of Chlamydia infections can be found in reference to the symptoms of 
trachoma in ancient Chinese and Egyptian manuscripts [4]. Two chlamydial species that 
commonly infect humans are Chlamydia trachomatis and Chlamydia pneumoniae. 
Human infections caused by Chlamydia are associated with blindness, sterility, and 
atherosclerosis, and have a tremendous impact on public health.  
C. trachomatis causes severe infections of the mucosal epithelium of eyes and 
urogenital tract, and has traditionally been classified into serovars based on the 
differential serospecificity to the major outer membrane protein (MOMP) [5]. Serovars A 
to C typically cause the ocular infection trachoma, which is the leading cause of 
preventable blindness worldwide [6, 7]. The number of people with active trachoma is 
estimated to be over 40 million, with additional 8.2 million people with trachomatous 
trichiasis, the blinding stage of the disease [8]. In addition to ocular infection, urogenital 
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tract chlamydial infections are the most commonly reported sexually transmitted bacterial 
infection with an estimated annual incidence of around 92 million cases in the world [9].  
Serovars L1 to L3 and their variants cause lymphogranuloma venereum (LGV), 
which is an invasive sexually transmitted infection (STI) with the dissemination of the 
infection to lymph nodes facilitated by macrophages [10, 11]. In contrast to LGV, genital 
infections caused by serovars D-K are restricted to the urogenital mucosa and commonly 
result in urethritis, cervicitis, and epididymitis [12]. The majority of C. trachomatis 
infections (approximately 70%) are asymptomatic, presenting problems in detection, 
treatment, and control [13]. Genital chlamydial infections, as STI in general, are of 
greater concern in women since the manifestation and consequences are more damaging 
to the reproductive health of women than men [14].  
C. trachomatis infections typically last for many months, and an estimated 15 to 
20% of acute genital Chlamydia infections are cleared spontaneously by adaptive 
immune responses [15, 16]. However, undetected and untreated infections can ascend to 
the upper genital tract and result in subsequent sequelae such as pelvic inflammatory 
disease (PID), which may lead to more severe complications including life-threatening 
ectopic pregnancy and infertility in women [17-19]. It is estimated that approximately 8-
10% of untreated C. trachomatis infections will progress to PID [20]. In addition, genital 
Chlamydia infection has been shown to associate with cervical cancer development and 
contribute significantly to increased rate of HIV transmission [21, 22]  
 C. pneumoniae is primarily a respiratory pathogen that causes acute upper 
respiratory tract infections. According to a serological study, more than 60% of adults 
have been infected during their lifetime [23]. Infection by C. pneumoniae is responsible 
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for an estimated 10% of community-acquired pneumonia and 5% of bronchitis and 
sinusitis cases [23]. Chronic infections by C. pneumoniae have also been associated with 
the development of chronic inflammatory conditions such as atherosclerosis [24], arthritis 
[25], asthma [26], and chronic obstructive pulmonary disease (COPD) [27].  
 
Current Challenge in Prevention and Treatment of C. trachomatis Infection 
Although Chlamydia infections are highly treatable with oral antibiotics, the 
effectiveness of antibiotic therapy approach in controlling the transmission of Chlamydia 
infection is limited due to the fact that the vast majority of infected individuals are 
asymptomatic and do not seek treatment. Despite decades of research effort, an effective 
vaccine is currently unavailable for prevention. While condom use is an effective barrier 
against the pathogen, many women are unable to negotiate consistent condom use with 
their sexual partners [28]. And therefore, more attention is now given to female-
controlled methods for the prevention of STI. 
When considering antibiotic therapy, bacterial resistance to antibiotics is an 
increasing clinical concern and threat to public health. Antibiotic resistance, however, has 
not been observed frequently with Chlamydia. This is because Chlamydia constitutes a 
distinct evolutionary lineage and grows within relative isolation, and their isolated niche 
limits the opportunity for acquisition of antibiotic resistance genes from other organisms 
[29]. Although repeated infections are relatively common (5 to 20%) for C. trachomatis 
infections under appropriate therapy, these repeated cases generally result from patient 
failure to comply with the proper regimen, rather than from emergence of antibiotic 
resistance [30].  
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The current recommended treatment is a 7-day regimen of doxycycline (a 
tetracycline derivative) or a single dose of azithromycin [31]. Tetracycline and its 
derivatives are considered treatment of choice for Chlamydia infections in both animals 
and humans, because they are effective, have low toxicity, and are cost effective, as 
opposed to more costly azithromycin [32, 33]. To date, the only reported case of 
antibiotic resistance acquired through horizontal gene transfer in Chlamydia species is the 
resistance mediated by the tet(C) island in a swine pathogen C. suis [34, 35]. In vitro 
horizontal transfer of the tet(C) island from C. suis to other species of Chlamydia 
including recent clinical C. trachomatis isolates was demonstrated by co-infection of cell 
culture [36]. Therefore, acquisition of tet(C) facilitated by contact between tetracycline-
resistant and -sensitive Chlamydia strains in a natural setting, and infection and selection 
in individuals treated with tetracycline is a possible scenario.  
 In addition, since asymptomatic infections escape detection and result in delayed 
diagnosis and treatment, the infected individuals unknowingly contribute to the spread of 
the infection and development of adverse reproductive complications. Screening and 
treatment programs have been implemented worldwide in an attempt to reduce the burden 
of Chlamydia and its sequelae. While the control program has contributed to a reduced 
incidence of PID [37], it has also been reported that the early detection and therapy 
attempts are associated with enhanced susceptibility to reinfection at the population level 
[38]. This phenomenon has been called the arrested immunity hypothesis and points out 
that early initiation of treatment leads to interruption of the acquisition of protective 
immunity [38].  
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Vaccination as a preventive strategy has made substantial progress towards 
eradication of certain infectious organisms [39]. The development of a protective vaccine 
for Chlamydia can significantly reduce the prevalence of infection. However, despite 
decades of research effort and progress, no protective vaccines are available for clinical 
use, and development of an effective vaccine against C. trachomatis remains a major 
challenge. It has been well demonstrated that previous exposure to C. trachomatis does 
not provide robust immunity against reinfection [13]. The initial approach of the whole-
organism based vaccine against trachoma using inactivated Chlamydia EBs was carried 
out by several groups [40-45]. Although these vaccines produced short-term protection 
evidenced by decreased incidence in onset of the disease, as well as decreased intensity 
of the disease in some individuals, they also resulted in heightened severity of disease 
when individuals subsequently became infected [46]. These observations lead to the 
assumption that both immunoprotective and immunopathogenic immune responses are 
induced by intact Chlamydia [46]. Therefore, despite significant success in clinical trials, 
the focus of vaccine research has shifted from whole-organism based to subunit vaccine 
to avoid the risk of immunopathology [47].  
For a successful vaccine against genital C. trachomatis, an antigen capable of 
stimulating both cell-mediated protective CD4+ Th1 response and B-cell antibody 
immunity in the genital mucosa is desirable [48]. Effective prevention of Chlamydia also 
requires a vaccine that provides coverage against the multiple naturally occurring 
C. trachomatis serovars [13]. Candidate chlamydial antigens can be categorized into four 
classes based on location and timing of expression during the developmental cycle [49]. 
The first class is the membrane proteins such as MOMP, outer membrane complex 
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protein B (OmcB), and polymorphic membrane proteins (Pmps). Surface exposed 
proteins are desirable targets for their susceptibility to antibody recognition, and also 
thought to be more efficient in inducing cellular immune responses than cytoplasmic 
proteins [50]. Other classes include chlamydial cytoplasmic proteins such as heat shock 
protein 60 (hsp60), inclusion membrane proteins such as various Inc proteins, and 
effector proteins of the type III secretion system (T3SS) that are secreted into host 
cytosol. 
 
Vaginal Microbicide 
Although immunization would be an ideal strategy for controlling the 
transmission of STIs, protective vaccines are currently unavailable for most STIs 
including C. trachomatis. New alternative prevention strategies are needed to combat the 
worldwide increase in STIs. Microbicides are vaginally or rectally administered 
compounds aiming at reducing the transmission of STIs across the mucosal tissue by 
forming a chemical, physical, and biological barrier against the pathogens. They can be 
formulated as various forms including gels, creams, foams, or vaginal rings. One 
advantage of microbicides over other preventative strategies such as condom use is that 
vaginal microbicides have the ability to greatly empower women, especially those who 
lack the societal or economic power, by allowing them to control their sexual health 
without the consent of the partner. Therefore, a successful microbicide is expected to 
provide women with an affordable self-managed option for prevention of STIs.  
The first vaginal microbicide to be tested was a commonly used spermicidal non-
specific surfactant nonoxynol-9 (N-9) [51-53]. The antiviral activity of N-9 in vitro was 
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first reported in 1985 [54, 55], which initiated the search for microbicides for prevention 
of sexual transmission of infectious pathogens. Evidence from both in vitro [54-56] and 
in vivo [57, 58] studies demonstrated activity of N-9 against human immunodeficiency 
virus (HIV). In addition to HIV, N-9 also inactivates other STI pathogens in vitro, 
including C. trachomatis [59-61] and herpes simplex virus [62, 63]. Multiple studies also 
reported in vivo activity of N-9 against C. trachomatis and N. gonorrhoeae [64-66]. 
However, it quickly became apparent that surfactant-based products perturbed the 
protective epithelial barrier among frequent users, potentially leading to increased 
transmission of infection [51, 53, 67]. These disappointing results led to discontinuation 
of the development of N-9 as a microbicide. More recently, after two decades of clinical 
trials testing a wide array of products, tenofovir, a nucleoside reverse transcriptase 
inhibitor, was tested in CAPRISA 004 trial and demonstrated to be moderately protective 
against male-to-female sexual transmission of HIV in a large-scale phase IIb clinical trial 
[68]. In this trial, 1% tenofovir gel reduced the acquisition of HIV-1 by 39% overall, and 
by 54% among women who used the gel correctly more than 80% of the time [68]. 
Due to the severity of the disease, the majority of microbicide research is focused 
on HIV prevention rather than other STIs. Although an effective microbicide is not yet 
approved for clinical use, over 70 microbicide candidates are currently in preclinical 
development [69]. There are several categories of compounds among the microbicide 
candidates in current trials, including vaginal defense enhancers, which facilitate the 
colonization of natural vaginal flora by maintaining the vaginal pH, surfactants, which 
disrupt the membrane of pathogens, and entry or replication inhibitors [70]. To date, four 
trials have assessed vaginal microbicide effects on C. trachomatis [71-74]. 
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Developmental Cycle of Chlamydia 
Despite their diversity of host range, disease pathology, and biological properties, 
Chlamydia species share the unique biphasic developmental cycle in which the organism 
exists in two morphologically and functionally distinct forms: metabolically inert 
infectious elementary bodies (EBs) and metabolically active noninfectious reticulate 
bodies (RBs) [75, 76] (Fig. 1.1). The infectious EBs are relatively small (approximately 
0.3 µm in diameter) and their nucleoid is highly condensed by chlamydial histone-like 
proteins Hc1 and Hc2 [77-79]. The outer membrane of EBs consists of proteins that are 
highly cross-linked by disulfide bonds, and the chlamydial outer membrane complex 
(COMC) is made up of a number of cysteine-rich proteins, ensuring osmotic stability in 
the extracellular environment [80, 81].  
Chlamydia infection is initiated by attachment of EB to the host cell surface 
followed by internalization into the host cell. The mechanisms of these processes are 
reviewed in the proceeding section “Chlamydial Attachment and Entry”. Upon entry, the 
EB resides within a membrane-bound parasitophorous vacuole, termed inclusion, which 
interacts with host vesicle trafficking pathways to acquire essential lipids [82-84]. 
Chlamydia actively remodels inclusion membrane to intersect exocytic pathway and 
avoid fusion with host cell lysosomes [85, 86]. Differentiation of EBs into larger (0.8 to 1 
µm in diameter) RBs begins immediately following internalization [76]. This transition 
involves events such as decondensation of chlamydial chromosome, early-gene 
transcription, and reduction of the disulfide-linked outer membrane of EB, which results 
in loss of rigidity [87-89]. For C. trachomatis LGV, the transition from EB to RB is 
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Fig. 1.1 Developmental cycle of Chlamydia trachomatis LGV. The infectious but 
metabolically inactive form of the organism, elementary body (EB) attaches to the 
host cell, where the bacterium induces its own endocytosis. After internalization, the 
EB remains within a parasitophorous vacuole, termed an inclusion, and differentiates 
to the non-infectious but metabolically active reticulate body (RB). RBs undergo 
multiple rounds of replication by binary fission before asynchronously transforming 
back into progeny EBs, which are subsequently released from the inclusion vacuole to 
infect neighboring cells. Under altered environmental conditions, such as presence of 
antibiotics, immunological responses, or nutrient and iron deprivation, Chlamydia 
enters a non-replicating and non-infectious persistent form, which is reversible when 
the stress is removed. Hours post infection (hpi) is indicated by blue numbers. 
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 complete by approximately 8 hour-post-infection (hpi). RBs undergo repeated cycles of 
binary fission to replicate within the expanding inclusion, leading to asynchronous 
differentiation back to EBs (~18 to 24 hpi) [90]. By 48 to 72 hpi, depending on the 
species, the developmental cycle is complete and Chlamydia are released from the host 
cell through two distinct mechanisms: cell lysis or a packaged release of Chlamydia 
termed extrusion [91]. Once released, progeny EBs proceed to initiate a new round of 
infection of neighboring cells.  
Under stressful growth conditions, Chlamydia can deviate from the normal 
developmental cycle and transition into a persistence state. Chlamydial persistence can be 
induced by a wide range of factors including the presence of antibiotics, immunological 
responses, or nutrient and iron deprivation [92, 93]. During persistence, Chlamydia forms 
morphologically aberrant RBs in which the organism remains viable and chromosomes 
continue to divide, but replication and differentiation to EBs are inhibited [94]. It has 
been suggested that Chlamydia uses this aberrant stage to survive and persist inside the 
host cell for extended periods of time and augment the disease process [47]. The normal 
developmental cycle can be generally recovered upon removal of the persistence-
inducing stimuli [93]. 
 
Chlamydial Attachment and Entry 
The initial interaction of Chlamydia with the eukaryotic cell membrane is a 
critical step in establishing a productive infection. However, the mechanisms governing 
the attachment and entry processes have been elusive. Although the natural targets of 
Chlamydia infections are mostly mucosal and submucosal surface, Chlamydia is capable 
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of efficiently infecting a wide range of non-phagocytic mammalian cells, suggesting that 
the chlamydial adhesins recognize conserved cellular receptors, or that multiple 
redundant strategies exist to ensure attachment and entry of the bacteria [90, 95]. 
Identification of chlamydial adhesins and host cell receptors involved in the attachment 
process has been complex, and no clear consensus on the overall process currently exists. 
This is thought largely due to distinct biological differences between various chlamydial 
species or serovars, as well as the use of different mammalian host cells [95].  
Chlamydial attachment is though to occur in a two-step process [95]. The initial 
attachment of many strains and species of Chlamydia with the host cell appears to be 
through reversible electrostatic interactions [96]. This interaction can be enhanced by the 
addition of divalent cations to neutralize the repulsive negative charges on the bacterial 
and host cell surface [96, 97]. Various studies have demonstrated the involvement of 
heparan sulfate-like glycosaminoglycans (GAGs) in this step [98-111]. Early studies 
determined that pre-treatment of the host cells with heparin inhibited chlamydial 
attachment [112, 113]. The involvement of heparan sulfate-like GAGs in the attachment 
of C. trachomatis L2 was demonstrated when the process was inhibited following pre-
treatment of EBs with heparan sulfate lyases, but this inhibition was reversible upon 
treatment of EBs with exogenous heparan sulfate [105]. With this observation, a 
trimolecular mechanism was proposed, in which soluble heparan sulfate serve as a bridge 
between the adhesion on the bacterial surface and the host cell receptor [105] (Fig. 1.2). 
Numerous studies followed and implied that heparan sulfate-like GAGs are required in 
the initial attachment process, although the degree of inhibition depended on the species 
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and serovars of Chlamydia, the host cell lines, and experimental settings [109, 111, 114-
119].  
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Fig. 1.2. Generalized model for chlamydial attachment to the host cells (adapted 
from Hegemann and Moelleken [126]). (A) Reversible interaction is via binding of 
OmcB to heparan sulfate (HS) and/or heparan sulfate proteoglycan (HSPG) via the 
bimolecular or trimolecular mechanism. HS and HSPG may be soluble form or 
associated with host cell surface. (B) Irreversible interaction. Pmp proteins bind to 
unidentified host cell receptors. Surface localized PFI and/or estrogen receptor (mER) 
may serve as a structural component of the host cell receptors.  
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One of the chlamydial proteins thought to bind GAGs is OmcB, which is the 
second most abundant outer membrane protein highly conserved among Chlamydia 
species [120]. Binding of OmcB and GAGs have been demonstrated by numerous studies 
including heparin affinity chromatography [99] and surrogate expression systems [103, 
121]. The GAG-binding domain has also been mapped to its N-terminal portion of the 
protein[99].   
Following the reversible step, an irreversible interaction of Chlamydia with host 
cell receptors takes place. This temperature-dependent irreversible process was originally 
demonstrated by analysis of chemically mutagenized Chinese hamster ovary (CHO) cell 
lines resistant to Chlamydia infection [122, 123]. Among numerous candidates, the 
family of Pmps has been identified as essential chlamydial adhesins [124, 125]. 
Substantial evidence has also been presented for involvement of Protein Disulfide 
Isomerase (PDI), which is a component of the estrogen receptor complex [126]. While 
many other host cell molecules have been proposed to play a role in this process, PDI is 
the only host cell protein that has been demonstrated to be essential for attachment of 
multiple species and serovars of Chlamydia [127]. A complex role of PDI in attachment 
was demonstrated by decreased binding of C. trachomatis to a CHO cell line containing 
defective PDI, where the inhibitory effect on chlamydial attachment was complemented 
by addition of full length PDI [127]. Subsequent study revealed that PDI is necessary for 
Chlamydial attachment. However, the bacteria do not bind directly to the host 
cell-associated PDI as a receptor, and rather binds to a cell surface protein that requires 
structural association with PDI [128]. A hypothetical model of chlamydial attachment 
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process based on the current understanding has been proposed by Hegemann and 
Moelleken and summarized in Fig. 1.2 [126].   
Similarly to the attachment process, various and sometimes conflicting studies 
have been reported regarding the multistep chlamydial entry, suggesting that Chlamydia 
may utilize multiple mechanisms to ensure their internalization, and the route is 
dependent on the chlamydial species or the host cell type [129]. Internalization of 
Chlamydia into the host cell occurs either by clathrin-mediated endocytosis, via caveolin-
rich domains, or lipid rafts [91, 130, 131]. For C. trachomatis, the predominant role of 
the clathrin-mediated entry has been reported [91]. Uptake of Chlamydia into non-
phagocytic host cells is actively induced by chlamydial factors. Regardless of the 
chlamydial species or host cell type, a common feature of Chlamydia entry is a small 
GTPase-dependent actin cytoskeleton remodeling at the site of entry [132]. Like many 
Gram-negative intracellular pathogenic bacteria, Chlamydia utilizes Type III secretion 
system (T3SS) to inject bacterial effector proteins into the host cell cytosol to modulate 
cellular responses [133]. Secretion of T3S effector proteins into the host cell immediately 
following the irreversible attachment step has been demonstrated [134]. A T3S effector 
protein, Tarp (translocated actin recruiting phosphoprotein), is conserved among all 
pathogenic Chlamydia species examined, and is associated with actin polymerization and 
cytoskeletal arrangement [134]. Tarp is present in EBs in an unphosphorylated state and 
translocated upon contact with host cells, where it is tyrosine phosphorylated by host cell 
kinase [134, 135]. One of the well studied host cell components demonstrated to play a 
critical role in this process is PDI. Interestingly, whereas the enzymatic activity of host 
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PDI is not required for chlamydial attachment, it has shown to be absolutely essential for 
the entry process [128].  
 
Chlamydia Lipooligosaccharide 
Lipopolysaccharide (LPS) is a major constituent of the outer membrane of 
Gram-negative bacteria, typically comprising approximately 10-15% of the total 
molecules in the outer membrane and estimated to make up about 75% of bacterial 
surface area [136]. LPS typically consists of three structural parts including lipid A, a 
core oligosaccharide, and an O-specific polysaccharide chain of repeating 
oligosaccharide units (Fig. 1.3 A). Since the original discovery as a toxin within heat-
inactivated Vibrio cholerae in 19th century, LPS has historically been known as heat-
resistant “endotoxin” [137]. Once released from the outer membrane of Gram-negative 
bacteria, LPS is recognized by the innate immune system via toll-like receptor 4 (TLR4), 
triggering production and release of a cascade of cytokines including tumor necrosis 
factor α (TNF- α), interleukin1 (IL1), and interleukin 6 (IL6) [138]. Systemic release of 
these inflammatory mediators during Gram-negative infection can lead to septic shock 
[139]. 
LPS is also recognized for the essential roles it plays in the pathogenesis and 
survival of Gram-negative bacteria. LPS contributes greatly to the structural integrity and 
stability of the outer membrane, and to the protection against the external stress factors 
surrounding the bacteria [140]. Owing to their surface exposure, LPS also plays a pivotal 
role in various interaction of bacteria and the host cell or the external environment. 
Specifically, LPS has been suggested to play a role in bacterial adhesion as well as being  
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Fig. 1.3. Chemical structure of E. coli Kdo2-Lipid A and Chlamydia Kdo3-LipidA. 
E. coli and Chlamydia differ in their 3-Deoxy-d-manno-octulosonic acid (Kdo) 
content and the number and chain length of fatty acid residues, but share a conserved 
glucosamine backbone. (A) E. coli Kdo2-Lipid A. (B) Chlamydia Kdo3-LipidA.   
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 a prominent virulence-determining factor for several Gram-negative organisms [141-
145].  
Like many other nonenteric mucosal pathogens, Chlamydia possesses 
lipooligosaccharide (LOS) rather than LPS in their outer membrane. Chlamydial LOS 
resembles a rough LPS of enterobacteria lacking the repeating O-antigen polysaccharide 
side chain present in a typical LPS (Fig. 1.3 B) [146]. All Chlamydiaceae share a family-
specific epitope composed of a trisaccharide of 3-deoxy-D-manno-oct-2-ulosonic (Kdo3) 
residues of the sequence α-Kdo(2→8)-α-Kdo(2→4)-α-Kdo, rather than a disaccharide 
(Kdo2) in LPS, whereas the lipid A contains a conserved glucosamine disaccharide 
backbone structure (1,4'-bisphosphorylated β(1→6)-linked) [146]. In contrast to enteric 
bacteria, chlamydial lipid A has been shown to exhibit low endotoxicity, reportedly due 
to the fewer number of hydrocarbons and the longer chain length [147, 148].  
Whereas LPS is an important structural component for the membrane integrity of 
Gram-negative bacteria, the outer membrane of Chlamydia EB harbors the intra- and 
intermolecular cysteine cross-linked proteins, which are expected to provide structural 
rigidity and stability [149, 150]. Nguyen et al. recently proposed the role of chlamydial 
LOS in the expression and stability of EB-specific outer membrane proteins [151]. It was 
demonstrated that the biosynthesis of chlamydial LOS was essential for production of 
infectious EBs. Specifically, the expression of an EB-specific outer membrane protein 
OmcB was inhibited in the absence of LOS while MOMP and Hc1, EB-specific histone-
like protein, were properly expressed.  
A general role of LOS in Chlamydia infectivity was reported by Fadel and 
Eley by demonstrating that infection of cell culture by C. trachomatis serovar LGV and 
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serovar E was inhibited in the presence of purified LOS, PMB, antibody 
against C. trachomatis LOS, and synthetic Kdo [152]. A role of chlamydial LOS in 
infection has also been suggested by Ajonuma and collegues [153]. It was demonstrated 
that CFTR (cystic fibrosis transmembrane conductance regulator) functions as a 
cell-surface receptor for entry and internalization of C. trachomatis, and LOS appears to 
be the ligand for CFTR [153]. Despite various studies and reports, the precise role of 
LOS in the developmental cycle of Chlamydia remains elusive.  
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Collaborator’s Contributions 
CellProfiler pipeline was designed and created by collaborative efforts of 
Dr. David Moore, Heather Shinogle, and Jeff Hills. Figure 2.1. “Overview of Image 
Analysis and CellProfiler Modules (Pipeline)” was generated by Jeff Hills. Taryn Cansler 
performed the preliminary studies in the development of the automated image-based 
method. 
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Chapter II.  
Development and Validation of Novel Analysis Methods for Chlamydia Infection 
  
Abstract 
The paucity of effective tools for large-scale compound screening is a major 
limitation in the identification of novel antichlamydial compounds. The conventional 
method for quantification of Chlamydia infection using fluorescence microscopy 
typically involves time- and labor-intensive manual enumeration, which is not applicable 
for a large-scale analysis required for an inhibitory compound screen. In this study, two 
methods are developed for rapid and accurate enumeration of Chlamydia infection in cell 
culture. An immunofluorescence image-based method was customized for fully 
automated quantification of Chlamydia infection using the freely available open-source 
image analysis software program CellProfiler and the complementary data exploration 
software program CellProfiler Analyst. The method yielded enumeration of different 
species and strains of Chlamydia, as well as the inhibitory capability of established 
antichlamydial compounds comparable to the conventional manual methods while 
drastically reducing the analysis time. In the second method, a redox indicator resazurin 
was utilized to measure Chlamydia infection by quantifying the redox capability of 
infected host cells. This assay also provided measurements comparable to those of the 
conventional microscopy method while reducing time and liquid-handling requirements 
for analysis. Overall, our studies show that two methods are highly effective tools for 
automated quantification of Chlamydia infection and assessment of antichlamydial 
activities. 
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Introduction 
A major limitation in the development of antichlamydial compounds is the lack of 
a well-established method for quantifying Chlamydia infection that is adaptable to a high-
throughput screening format. The paucity of high-throughput screening methods is 
heavily influenced by the obligate intracellular growth characteristics and the inability for 
axenic cultivation of Chlamydia. The standard technique for quantification of Chlamydia 
infection is the immunofluorescence assay (IFA), which relies on visual detection of 
fluorescently stained bacteria and host cells, typically within a relatively low number of 
fields (e.g., 3 to 10). This process is labor-intensive and not suitable for large-scale 
screening required for antimicrobial compound development. The limitations of manual 
enumeration are evident; the process is labor intensive, field selection is prone to 
subjectivity, and results are based on a relatively restricted data set. 
In this chapter, we describe two novel methods that were developed for rapid 
enumeration of Chlamydia infection in cell culture. The first method is an 
immunofluorescence image-based method, which was customized for fully automated 
quantification of Chlamydia infection using the freely available open-source image 
analysis software program CellProfiler and the complementary data exploration software 
program CellProfiler Analyst [154]. In the second method, an alamarBlue (resazurin) 
assay was adopted to measure Chlamydia infection by quantifying the redox capability of 
infected host cells [155]. 
CellProfiler is freely available open-source computational image analysis 
software (http://www.cellprofiler.org), which has been shown to be an effective tool for 
quantifying visual information in a variety of biological images, particularly in large-
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scale imaging experiments [156]. The complement software, CellProfiler Analyst, 
performs analysis of image-derived quantitative information as defined within a very 
large collection of image-feature measurements (i.e., a cytological profile) produced by 
CellProfiler. CellProfiler Analyst contains a supervised machine-learning system that is 
intuitive for development of image analysis algorithms via visual perception using a user-
friendly interface [157, 158] 
CellProfiler and CellProfier Analyst were adapted for identification and 
enumeration of Chlamydia infection. For validation of the method, cell culture infections 
of the commonly utilized laboratory strain (LGV-2) and the more clinically relevant 
strain (serovar D) of C. trachomatis were analyzed. The accuracy and expediency of the 
automated method were compared to those of the conventional visual inspection. To 
evaluate the efficacy of the method to identify antichlamydial compounds, infections 
were measured following treatment with four anti-Chlamydia molecules (tetracycline 
[159, 160], polymyxin B [161-163], hydroxyethyl cellulose [164], and anti-C. 
trachomatis polyclonal antibody) that have contrasting mechanisms of inhibitory activity 
toward Chlamydia. 
While the IFA-based assay, which allows visualization of host cells and bacteria, 
is the preferred approach for accurate quantification of the intercellular growth of 
Chlamydia, automation of image acquisition requires specialized instrumentation such as 
an automated fluorescence microscope and extensive computational resources, which 
may not be readily available in some laboratories. Therefore, we thought to develop a 
facile and inexpensive method using a microplate spectrophotometer.  
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AlamarBlue (resazurin) is a colorimetric cell viability indicator widely used to 
monitor eukaryotic cell proliferative activity [165-167]. The redox dye resazurin enters 
the cytosol in the oxidized form (blue) and is converted to the reduced form, resorufin 
(red) [168]. The reduced and oxidized forms of alamarBlue can be separately measured 
by a spectrophotometer and used to determine the reduction capability of cells, which 
reflects the status of mitochondrial function and cell viability. One significant advantage 
of alamarBlue over other metabolic indicators is that the compound allows continuous 
monitoring of cells [169]. This is due to the fact that the compound does not interfere 
with the activity of the respiratory chain and, therefore, is nontoxic to the cells [169]. 
AlamarBlue has found applications in quantitative analysis of cell viability [170], 
proliferation [171], cytotoxicity [172], and drug susceptibility [173, 174] in both bacterial 
and eukaryotic systems as well as high-throughput screening of antimicrobial compounds 
in microorganisms such as Mycobacterium tuberculosis [175] and Staphylococcus aureus 
[176]. In this study, alamarBlue assay was adapted for enumeration of C. trachomatis 
infection by measuring the lysis of infected host cells as indicated by a decrease in cell 
viability. Similar to the validation study for the image-based assay, the ability of the 
alamarBlue assay to evaluate anti-Chlamydia activity was assessed by measuring 
Chlamydia infection levels in the presence of the well-established inhibitors. 
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Materials and Methods 
Bacteria and cell culture  
C. trachomatis lymphogranuloma venereum (LGV) serovar L2/434/Bu EBs were 
purified from infected L929 cells using a 30% Renografin density gradient as previously 
described [177], and stored in sucrose phosphate glutamate (SPG) at -80°C until use. 
C. trachomatis serovar D/UW-3/Cx was isolated from infected HeLa 229 cells and 
C. muridarum strain Nigg was purified from infected L929 cells as previously described 
[177]. L929 cells and HeLa 229 cells were routinely cultured in RPMI 1640 tissue culture 
medium (Mediatech, Inc., Manassas, VA) supplemented with 5% fetal bovine serum 
(FBS) (Thermo Fisher Scientific, Liverpool, NY) and 10 µg/mL gentamicin (MP 
Biomedicals, Santa Ana, CA) at 37°C in a humidified atmosphere of 5% CO2. Cells were 
plated in 96-well plates (Bioexpress, Kaysville, UT) at density of 7 x 104 cells/mL, 
200 µL/well, and incubated overnight prior to infection. In order to minimize edge effect 
(well-to-well variations in number of cells), plated cells were incubated for 1 h at room 
temperature prior to incubation at 37°C in an atmosphere of 5% CO2, as previously 
described [178]. 
 
Microbicide and antibiotic preparation 
Polymyxin B sulfate (Enzo Life Science, New York, NY) and tetracycline 
hydrochloride (USB Corporation, Cleveland, OH) were obtained in powder form. Stock 
solution of polymyxin B sulfate was prepared in Hank’s Buffered Salt Solution (HBSS, 
Mediatech, Inc., Holly Hill, FL) to a concentration of 10 mM. Tetracycline was dissolved 
in sterile water to a stock concentration of 1 mg/mL. Hydroxyethyl cellulose (HEC, 
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90 kDa, Sigma-Aldrich, St. Louis, MO) was prepared as a stock solution at a 
concentration of 12% w/v in water. The HEC gel (polymeric liquid) was adjusted to pH 
4.5 using 10 M NaOH and stored at 4°C. At the time of the assay, 12% HEC gel was 
diluted to a final concentration of 2.8% w/v in phosphate buffered saline (PBS). The 
mixture was shaken for 1 h at 37°C to achieve a uniform solution, centrifuged for 1 min 
at 300 x g to remove any bubbles, adjusted to pH 7.0, and stored at 4°C until use.  
 
EB dilution assay  
Purified C. trachomatis L2 EBs were serially diluted two-fold in HBSS and 
transferred to ~70% confluent L929 cell monolayers (90 µL/well) in a 96-well plate. 
Ninety µL of HBSS alone was added to mock-infected control cells. Cells were incubated 
for 2 h at room temperature. Following the incubation period, the bacterial inocula were 
removed and cells were washed once with 200 µL of HBSS. Two-hundred µL of fresh 
medium (RPMI/5% fetal bovine serum/10 µg per mL gentamicin) was added to each well 
and cells were incubated at 37°C in an atmosphere of 5% CO2 for 24 h.  
 
Antichlamydial compound inhibitory assay  
C. trachomatis L2 EBs were diluted in HBSS. Polymyxin B and hydroxyethyl 
cellulose were serially diluted two-fold in HBSS containing EBs to the concentration 
range of 1 mM to 15.625 µM and 2.8% to 0.175%, respectively. Compound-EB mixtures 
were incubated for 60 min at room temperature. Compound-treated EB inocula were 
mixed using a multi-channel pipette (LabNet Excel, Edison, NJ) at the start and end of 
the incubation period to ensure uniformity of the inocula. The mixtures containing the 
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compound and EBs were then transferred to ~70% confluent L929 cell monolayers in a 
96-well plate and incubated at room temperature for 2 h. Following the incubation period, 
the inocula were removed and cells were washed once with 200 µL of HBSS. Two-
hundred µL of fresh medium (RPMI/5% fetal bovine serum/10 µg per mL gentamicin) 
was added to each well. For tetracycline treatment, fresh medium containing appropriate 
concentration (0.1-0.7 µg/mL) of tetracycline was added following two-hour inoculation 
period. Cells were incubated at 37°C in an atmosphere of 5% CO2 for 24 h.  
 
C. trachomatis serovar D and C. muridarum infection  
Purified C. trachomatis serovar D or C. muridarum were diluted four-fold in 
HBSS and transferred to ~70% confluent HeLa 229 or L929 cell monolayers (90 
µL/well) in a 96-well plate, respectively.  Ninety µL of HBSS alone was added to mock-
infected control cells.  The plate was centrifuged at 900 x g for 1 h at room temperature 
[177].  Following the incubation period, chlamydial inocula were removed and cells were 
washed once with 200 µL of HBSS.  Two-hundred µL of fresh medium (RPMI/5% fetal 
bovine serum/10 µg per mL gentamycin) was added into each well and cells were 
incubated at 37°C in an atmosphere of 5% CO2 for 48 h for serovar D and 24 h for C. 
muridarum before they were analyzed.  
 
Neutralization Assay 
Guinea pig polyclonal serum against Chlamydia L2 EB was purchased from 
Abcam (Cambridge, MA). Rabbit polyclonal anti-RpoA antibody was affinity-purified 
using the AminoLink Plus Immobilization Kit (Thermo Scientific, Rockford, IL). Protein 
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concentration of purified antibody was determined to be 1.01 mg/mL by Bradford assay 
(Bio-Rad Laboratories, Hercules, CA).  Sera and purified antibody were serially diluted 
(five-fold at each step) in HBSS. Prior to infection, purified C. trachomatis L2 EBs were 
added to each sera- or purified antibody- sample and incubated for 30 min at 37°C to 
allow interaction between EBs and the antibody to take place [179]. HBSS alone was 
used as negative control. Following the incubation period, 90 µL of each sample 
containing antibody-EB mixture was added to a monolayer of L929 cells in a 96-well 
plate and incubated at room temperature for 2 h.  After the incubation period, inocula 
were removed and cells were washed once with HBSS. Two-hundred µL of fresh 
medium (RPMI/5% fetal bovine serum/10 µg per mL gentamycin) was added to each 
well and cells were incubated at 37°C for 24 h. 
 
Immunofluorescence assay (IFA) 
At 24 or 48 hours post infection (hpi) for serovar L2 or D, respectively, infected 
cells were fixed with 100% methanol (200 µL/well) for 10 min at room temperature and 
washed once with PBS. Cells were stained with MicroTrack C. trachomatis culture 
confirmation test (Syva Co., Palo Alto, CA) diluted to 1:40 in PBS (50 µL/well) for 60 
min in the dark, followed by a 5 min stain with 1 µg/mL DAPI in PBS (50 µL/well). 
DAPI was removed and PBS (200 µL/well) was added. Plates were stored in the dark at 
4°C until imaging. 
 
Image Acquisition  
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Images were automatically captured with a BD Pathway BioImager 855 
microscope (Becton, Dickinson and Company, Franklin Lakes, NJ) with a 20x, 0.4 
numerical aperture objective, fully equipped for multi-color capture, and an Orca ER 
camera (Hamamatsu Photonics, Bridgewater, NJ). The system was controlled by 
Attovision collection software (Becton, Dickinson and Company, Franklin Lakes, NJ), 
with automated infrared and image autofocus capture for 15 fields per well for a 96-well 
plate. Multiple plate capture was enabled by a Twister II robotic arm (Caliper 
Lifesciences Inc., Hopkinton, MA), which was integrated with the Attovision software.  
 
Image Analysis, CellProfiler and CellProfiler Analyst  
Images acquired by automated microscopy were loaded into the open-source 
software CellProfiler (Broad Institute, Cambridge, MA), followed by segmentation of 
images and identification of objects. Four main steps of the process were segmentation of 
nuclei, identification of whole cells, segmentation of chlamydial inclusions, and 
tabulation of measurements (Fig. 2.1). The first task performed by CellProfiler was 
identification of the objects. Using CellProfiler modules, the nuclei, referred to as 
primary objects within CellProfiler, were identified first from the DNA–stained images. 
Once the nuclei had been identified, the subsequent module used the whole cell-stained 
images and previously identified nuclei to identify the cell boundaries (whole cell), which 
were referred to as secondary objects. The area of the identified nuclei was subtracted 
from the whole cells to identify the cytoplasm, referred to as tertiary objects. For 
identification of chlamydial inclusions, CellProfiler expanded each area of nuclei by 15 
pixels and used this expanded region to search for inclusions. Inclusions were then  
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Fig. 2.1. Overview of Image Analysis and CellProfiler Modules (Pipeline). (A) Images 
are acquired in three separate colors by automated microscopy. (B) A sequential image 
analysis commands are performed by CellProfiler based on a customized pipeline. 
Identification of nuclei, chlamydial inclusions, and whole-cell were performed first. 
(C) Following identification, measurements were collected for each objects and 
cytological profile of each cell was generated. 
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identified and segmented. The second task performed by CellProfiler was generating a 
cytological profile of each cell. CellProfiler measured a large number of cellular and 
subcellular features once all objects (nuclei, cells, cytoplasm and identified chlamydial 
inclusions) had been identified. These quantitative measurements consist of apparent 
cellular and sub-cellular features as well as an extensive amount of less evident details 
such as intensity of the stain, size, shape, and pixel correlation between objects. Once 
these measurements were taken, the cytological profile was created for each cell to be 
utilized by CellProfiler Analyst (Broad Institute, Cambridge, MA) and exported to a 
spreadsheet. Both nuclei and chlamydial inclusions were related to the identified cells so 
that each inclusion was assigned to only one nucleus. For enumeration of inclusion 
forming units (IFU), the last module within the pipeline (ExportToDatabase) was 
modified to allow for classification of individual inclusion rather than cells by 
CellProfiler. To enumerate infected cells, the cytological profiles were loaded into 
CellProfiler Analyst. Random images each containing a single cell were presented to 
initiate the training process. Approximately twenty images from the positive (infected) 
and negative (uninfected) controls were manually classified by dragging and dropping the 
images into the appropriate bins within the CellProfiler Analyst interface (Fig. 2.2A). 
Based on the cytological profiles of these classified cells, CellProfiler Analyst identified 
the parameters necessary to accurately distinguish between uninfected and infected cells 
by generating a set of 50 rules (i.e. parameters). The software then presented a new set of 
cells that had been classified as positive or negative based on the rules generated. Any 
cells classified inaccurately were manually sorted into the appropriate bin to continue the 
training process. To assess the accuracy of the training, images from selected wells were  
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Fig. 2.2. CellProfiler Analyst Drag and Drop Interface. (A) CellProfiler Analyst 
randomly presents cells to be manually classified using a drag and drop interface. 
Each cell is sorted into either infected or uninfected category. Rules are generated 
based on the classified cells and used to automatically distinguish between infected 
and uninfected cells. (B) A classified image of any well among the experiment can be 
opened to assess the accuracy of the classifications. A blue label represents an infected 
cell and an orange label represents an uninfected cell based on the current rule-set. The 
figure represents a portion of a classified image.  
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opened and individual cells were automatically marked as uninfected or infected by 
CellProfiler Analyst based on the established rules (Fig. 2.2B). Any cell that had been 
classified incorrectly was manually reassigned to the appropriate bin. After the 
correction, a set of refined rules was generated and used to score every cell in every 
image. These steps were repeated until the system was able to accurately classify greater 
than 95% of cells into the correct category. Upon completion of scoring, a spreadsheet 
containing the number of positive and negative cells for each well was generated and 
exported.  
 
AlamarBlue cytotoxicity assay 
L929 cells were seeded in 96-well flat-bottom tissue culture plates (BD 
Biosciences, Billerica, MA) at a density of 8 x 104 cells/well and cultured until confluent 
monolayers were formed. Purified C. trachomatis was serially diluted 10-fold in Hank’s 
Buffered Salt Solution (HBSS) (Mediatech, Inc.) and added to host cell monolayers (90 
μL/well). Ninety-μL of HBSS alone was added to mock-infected control cells.  For 
indicated experiments, purified C. trachomatis were prepared in HBSS containing 500 
μM of polymyxin B and incubated for 30 minutes.  Plates were incubated for 2 h at room 
temperature.  After infection, the chlamydial inocula were removed and cell monolayers 
were washed with HBSS followed by addition of phenol red-free RPMI culture medium 
(200 μL/well) supplemented with 5% FBS, 300 μg/mL glutamine (Invitrogen, Carlsbad, 
CA), 50 μg/mL vancomycin, and 1 μg/mL cycloheximide. The infection proceeded until 
the indicated time points. At each indicated hours after infection, 22 μL of alamarBlue 
reagent (Invitrogen, Carlsbad, CA) was directly added to the medium resulting in a final 
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concentration of 10%. The plates were incubated at 37 °C.  After 8 h of incubation with 
alamarBlue, the absorbance was obtained in a PowerWave microplate spectrophotometer 
at 570 nm (reduced) and 600 nm (oxidized) with KC4 data collection and analysis 
software (BioTek Instruments, Inc., Winooski, VT).  For experiments with multiple time 
points, plates were kept in the incubator at 37 °C between the time points.  The results 
were expressed as the percentage of alamarBlue reduced by infected host cells relative to 
alamarBlue reduced by the mock-infected control cells using a formula provided by the 
manufacture: 
           x100, where εox = molar extinction coefficient of 
alamarBlue oxidized form, εox = molar extinction coefficient of alamarBlue reduced form, 
A = absorbance of test wells, A’ = absorbance of positive control well (mock-infection), 
λ1  = 570 nm, and λ2= 600 nm.   
  
€ 
(εox )λ2Aλ1 − (εox )λ1Aλ2
(εox )λ2A'λ1 − (εox )λ1A'λ2
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Results 
Method development and initial validation for the automated image-based method 
Many of the challenges associated with accurate identification and enumeration of 
Chlamydia infections using an image-based method are due to diversity of inclusion 
maturation and size. For instance, depending on the chlamydial species or serovar, 
different time points need to be selected for accurate identification of chlamydial 
inclusions by immunofluorescent analysis. Additionally, in C. trachomatis infected cells, 
the size of inclusions may vary greatly depending on how many EBs have infected a 
single cell. This is because multiple EBs can infect a single cell and individual inclusions 
can fuse to form a much larger inclusion. Inclusion fusion of LGV strains of C. 
trachomatis has been reported to begin by 10 hpi [180, 181]. Due to these variables in 
chlamydial development, image-based quantification of inclusions based on limited 
numbers of predefined parameters are likely to result in compromised accuracy and 
sensitivity. The ability of CellProfiler to automatically extract quantitative cellular and 
subcellular features, along with the machine-learning aspect of CellProfiler Analyst were 
expected to be powerful tools to overcome these challenges by eliminating the need for 
investigators to define threshold values.  
To begin testing the capability of CellProfiler and CellProfiler Analyst to 
accurately identify and quantify C. trachomatis infection, L929 cells infected by the 
widely utilized LGV serovar L2 strain were analyzed 24 hpi. Following image 
acquisition by fluorescence microscopy, CellProfiler segmented individual cells and 
generated a cytological profile for each cell by measuring hundreds of cellular and 
subcellular features. Using these cytological profiles, supervised classification features of 
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CellProfiler Analyst were incorporated. To begin a training session, CellProfiler Analyst 
presented a random selection of cells, of which 20 to 30 infected (positive) or uninfected 
(negative) cells were sorted into a corresponding bin via manual inspection (Fig. 2.2A). 
Based on the quantitative measurements within the cytological profiles of manually 
sorted cells, CellProfiler Analyst developed a differential rule-set (machine-learning 
algorithms). To evaluate this initial rule-set, the accuracy of classification was assessed 
for a small set of cells (~1000 cells) (Fig. 2.2B). When errors were detected in 
classification among this population of cells, additional training sessions were performed 
to refine the rule-set. These steps were repeated until the system was able to accurately 
classify greater than 95% of cells into infected or uninfected category. The process 
typically took manual classification of 30 to 50 infected and uninfected cells. 
To validate the effectiveness of CellProfiler Analyst training process, the 
differential rule-set was applied to an image acquired from populations of cells that were 
not used in the training process. For an image representative of 15 fields of view, the total 
number of cells and the number of inclusion positive cells were counted using both the 
automated method and the conventional manual inspection (Table 2.1). The automated 
method reported a total of 1808 cells, out of which 699 cells were classified as inclusion 
positive. The number of total cells and inclusion positive cells reported by manual 
inspection were 1884 and 734, respectively. The percent infection calculated based on 
these numbers reported by the automated method and manual inspection were 38.7% and 
39.0%, respectively. It was noted that the vast majority of cells that were classified as 
uninfected by CellProfiler Analyst but identified as infected by manual inspection were 
within highly confluent regions of the sample, where cellular boundaries were not evident  
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Table 2.1. Comparison of automated and manual methods for C. trachomatis enumeration. 
 
a The percent cell infection was calculated by dividing the number of inclusion positive cells by the total number of cells.  
b The number of inclusions visualized by FITC-labeling.  
c IFU/mL was calculated by dividing the number of IFU by the volume of EBs used for infection (90 µL).  
d Percent difference between  the values reported by automated method and manual counting.
 Automated Manual Percent difference d 
Number of L929 Cells  1808 1884 4.12% 
Number of Inclusion Positive Cells  699 734 4.88% 
Percent Infection a 38.7% 39.0% 0.77% 
Number of IFU b 898 931 3.61% 
IFU per milliliter c  9.98 x 103 1.03 x 104 3.61% 
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and cells were often multinucleated. Together, these results strongly support that 
enumeration using the automated method was highly comparable to the conventional 
manual inspection.  
 
Application to large-scale format  
To evaluate the suitability of this automated method for large-scale application, 
image acquisition and quantification of Chlamydia infection were performed in a 96-well 
plate format. Sensitivity of the method was examined by measuring the infection level of 
cells infected with two-fold serial dilutions of C. trachomatis EBs. The reproducibility 
and precision of the method were assessed through infections by different aliquots from 
the same EB preparation. The use of CellProfiler and CellProfiler Analyst allowed 
simultaneous analysis of a total of 1080 images (72 samples, 15 image-fields per sample) 
within a 96-well plate. These samples included sets of eight two-fold serial dilutions of 
EBs in triplicate from three separate aliquots. Although a slight variance in values among 
the aliquots was observed, all three aliquots followed a highly similar trend of decrease 
across a dynamic range of infections, ranging from 89.7% to 3.7% (Fig. 2.3). Correlation 
coefficient values were greater than 0.99 between any of the aliquots suggesting that the 
three sets of data are highly correlated and similar, as anticipated for the three aliquots 
containing nearly identical number of infectious EBs. Standard deviations among the 
triplicates were less than 3.5% in all samples. Together, these data indicate that the 
automated method is capable of performing highly reproducible analysis among a large 
set of samples with high sensitivity (a dynamic range of infections) and precision (low 
standard deviations). 
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Fig. 2.3. Comparison of automated and manual enumeration of C. trachomatis 
serovar L2 infection in 96-well format. Percent infectivity was determined for a two-
fold dilution series of C. trachomatis EBs 24 hpi by automated and manual 
enumeration methods from the same samples for comparison of sensitivity, 
reproducibility, and precision. For the automated method, percent infectivity was 
calculated based on the number of infected and uninfected cells identified by 
CellProfiler Analyst. Error bars indicate standard deviation of the triplicate wells. For 
manual enumeration, cells and inclusions were counted in the three randomly selected 
fields from one of the triplicate wells. Error bars represent standard deviation of the 
mean of the three fields.  
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In order to compare the accuracy and efficiency of the automated method to the 
conventional manual inspection, manual counting of infected and uninfected cells were 
performed in three randomly selected fields of view from the immunofluorescent-images 
acquired for the automated method. Similar to the automated method, a dose-dependent 
decrease in infectivity over two-fold dilution of EBs was observed (Fig. 2.3). When the 
datasets obtained using the automated and manual methods were compared, the 
correlation coefficient between the two datasets was greater than 0.99 for all three 
aliquots, demonstrating that these datasets acquired by the two methods were highly 
comparable to each other.  
 
Validation of the automated method with known chemical inhibitors 
The ability of the automated method to accurately assess the inhibitory activities 
of compounds against Chlamydia infection was demonstrated using three previously 
known antichlamydial compounds that inhibit different stages of the developmental 
cycle: tetracycline, hydroxyethyl cellulose (HEC), and polymyxin B (PMB). Tetracycline 
is a broad-spectrum antibiotic, for which Chlamydia is known to be exquisitely sensitive. 
Tetracycline interferes with the metabolic process of Chlamydia by targeting translational 
machinery and inhibiting protein biosynthesis [159]. Complete inhibition of inclusion 
formation by tetracycline at a concentration of 0.51 µg/ml has been previously reported 
[160]. L929 cells were infected with C. trachomatis and treated with various compounds 
in a 96-well plate, and analyzed 24 hpi following automated image acquisition. The 
analysis by the automated method reported antichlamydial effect of tetracycline in a 
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dose-dependent manner with complete inhibition of inclusion formation at 0.5 µg/ml, an 
inhibitory concentration consistent with the previous report [160] (Fig. 2.4). 
HEC is a common polysaccharide excipient used in vaginally delivered microbicides for 
STIs. Although excipients are typically used as delivery vehicles and are expected to be 
pharmacologically inactive, a 90-kDa HEC has been shown to have an inhibitory effect 
on C. trachomatis infection, purportedly as a competitive inhibitor for adhesion [164]. 
When EBs were treated with HEC, the inhibitory effect of HEC was directly proportional 
to the concentration in the range of 0.175% to 0.7% and reached complete inhibition at 
1.4% (Fig. 2.4B). This proportionality between the concentration and the inhibitory effect 
supports a previously suggested mechanism for HEC inhibition, that HEC may act as a 
competitive inhibitor by competing with the host cell for the recognition site on the 
chlamydial surface [164].  
PMB is an antibiotic that typically acts by disrupting the outer membrane of 
gram-negative bacteria through interaction with the lipid A portion of lipopolysaccharide 
[182, 183]. PMB is active against nearly all species of gram-negative bacteria, including 
C. trachomatis, and has been used as a positive control for antichlamydial activity in 
numerous studies[161-163]. In contrast to HEC treatment, when EBs were treated with 
PMB, the concentration of the inhibitor did not show a proportional effect on inclusion 
formation, suggesting a mode of inhibition different from that of HEC. In addition, 
complete inhibition of inclusion formation was not achieved even at the highest 
concentration of PMB, reaching maximum inhibition of approximately 70% at 500 µM. 
Interestingly, previous studies show dose-dependent antichlamydial activity by PMB that 
plateaued without reaching complete inhibition [161, 184]. 
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Fig. 2.4. Inhibitory properties of known inhibitors on C. trachomatis serovar L2 
infection. Inhibitory activities of three known anti-chlamydial compounds 
tetracycline, 90 kDa HEC, or PMB were determined using the automated image-based 
assay. Percent inhibition was calculated relative to the wells without treatment 24 hpi. 
(A) Tetracycline treatment. L929 cells were infected with C. trachomatis and 0.1, 0.2, 
0.3, 0.4, 0.5, 0.6, or 0.7 µg/mL of tetracycline was added along with growth medium. 
Error bars indicate standard deviation of the mean of triplicate wells. (B) 90 kDa HEC 
treatment. L929 cells were infected with C. trachomatis pre-incubated with decreasing 
concentration of 5.6 to 0.175% of HEC for an hour prior to infection. Error bars 
represent the standard deviations of the mean of triplicate wells. (C) PMB treatment. 
L929 cells were infected with C. trachomatis pre-incubated with decreasing 
concentration of 1000 to 15.625 µM of PMB for an hour prior to infection. Error bars 
represent the standard deviations of triplicate wells. 
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Efficacy of the automated method for measuring neutralizing antibodies 
Given the current lack of an effective vaccine against Chlamydia, identifying and 
evaluating neutralizing antibodies would be extremely advantageous. The automated 
method was used to examine inhibitory properties of polyclonal sera for chlamydial EBs. 
Affinity-purified polyclonal antibody against C. trachomatis RpoA (bacterial cytosol 
RNA polymerase α subunit) was used as a negative control. C. trachomatis EBs were 
pre-treated with anti-Chlamydia EB serum or affinity-purified polyclonal anti-RpoA 
antibody prior to inoculation of L929 cells, and infection levels were analyzed 24 hpi. At 
the highest dose (1:100 dilution), anti-Chlamydia serum inhibited infection by 98.7% 
relative to the infection level of the untreated control samples (Fig. 2.5). Anti-RpoA 
antibody treatment showed insignificant neutralization activity, demonstrating that the 
neutralization activity of anti-Chlamydia serum was not due to a nonspecific reaction. 
When the amount of anti-Chlamydia serum reduced by 5-fold (1:500 dilution), the 
inhibitory effect was reduced to 44.1%. No inhibitory effect was observed at the lowest 
concentration (1:2,500). Together, these results indicate that this automated method may 
be used to accurately identify neutralizing antibody and protective concentrations for 
Chlamydia infection in cell culture. 
 
Assessment of the automated assay with C. trachomatis serovar D and the mouse 
Chlamydia species C. muridarum  
Due to the relative ease of cultivation and shorter developmental cycle, LGV 
serovar L2 is a commonly used C. trachomatis prototype strain in chlamydial research.  
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Fig. 2.5. Inhibitory properties of anti-Chlamydia sera on infectivity of 
C. trachomatis L2 EBs. The ability of anti-Chlamydia sera to neutralize the infectivity 
of C. trachomatis L2 EBs was evaluated using the automated image-based method. 
L929 cells were infected with C. trachomatis EBs pre-incubated with various 
concentrations of anti-RpoA antibody or anti-Chlamydia sera for 30 min prior to 
infection. Percent inhibition was calculated relative to the wells without treatment 
following 24 hr incubation. ND=No inhibition was detected. Error bars indicate 
standard deviation of the triplicate samples. 
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However, trachoma serovars D, E, and F are the most prevalent urogenital strains of 
C. trachomatis worldwide and therefore of more clinical relevance [185]. C. muridarum 
is a natural pathogen of mice and is commonly used as a model for infection of the 
human genital tract caused by C. trachomatis. 
HeLa 229 cells or L929 cells were infected with 4-fold serial dilutions of serovar D or 
C. muridarum, respectively. HeLa 229 cells were used to demonstrate that various 
eukaryotic cells may be used as host cell lines for the automated enumeration. Due to the 
longer developmental cycle of serovar D than of L2, serovar D infections were quantified 
48 hpi and C. muridarum was quantified 24 hpi. The automated method reported the 
infection level, ranging from 81.9% to 14.0% for serovar D and 95.7% to 4.8% for C. 
muridarum in a dose-dependent manner (Fig. 2.6). These results support that accurate 
enumeration of Chlamydia infection by the automated method is highly adaptable to 
different serovars and species of Chlamydia despite the differences in the duration of 
developmental cycle, and eukaryotic host cell lines. 
 
Percentage of cells infected and total inclusion forming units 
Quantification of Chlamydia infection typically utilizes two approaches; inclusion 
forming unit per milliliter (IFU/mL) or percentage of cells infected. IFU per milliliter is 
determined by enumerating individual inclusions formed in a given population of cells 
and dividing the number of total IFU by the volume of EBs used for infection. Percentage 
of infected cells is defined by the relative number of infected cells compared to the total 
number of cells (infected and uninfected). The percent infection approach considers well-
to-well variation of eukaryotic cell number often observed within microplates, and  
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Fig. 2.6. Automated enumeration of C. trachomatis serovar D and C. muridarum 
infection. Percent infectivity for a four-fold dilution series of (A) C. trachomatis 
serovar D and (B) C. muridarum were determined by the automated method. 
Infections were performed in triplicate wells for each dilution. Percent infectivity was 
calculated based on the number of infected and uninfected cells identified by 
CellProfiler Analyst. Error bars indicate standard deviation of the triplicate wells. 
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therefore, is advantageous in applications such as inhibitory compound screening. The 
number of IFU within a given well is largely influenced by the number of cells available 
for EBs to infect. Therefore, well-to-well variation of host cell number must be 
considered in order to make relative comparisons of the infection levels among different 
wells. On the other hand, when solely considering the number of inclusions formed, the 
automated method may lead to underestimation of the number of inclusions. This is 
because the automated method utilizes a binary classification and does not reflect on how 
many inclusions are present in a single cell when multiplicity of infection (MOI) is 
greater than one. To demonstrate that this automated method could be easily adapted for 
chlamydial quantification using both of these approaches, a minor modification was 
applied to the CellProfiler pipeline. Specifically, the last module within the pipeline 
(ExportToDatabase) was modified to facilitate classification of individual inclusions 
rather than cells by CellProfiler Analyst (Fig. 2.1C). As a result, CellProfiler Analyst was 
successfully trained to distinguish between productive inclusions and aggregation of EBs 
or background staining. The precision of the automated method relative to the 
conventional manual inspection in determining IFU was examined (Table 2.1). IFU per 
milliliter calculated from the number of IFU reported by the automated methods and 
manual inspection were 9.98 x 10-3 and 1.03 x 10-4, respectively. These data demonstrate 
that the automated method can be used for accurate quantification of Chlamydia infection 
by both of the two commonly used approaches.  
 
Adaptation of alamarBlue cytotoxicity assay for quantification of Chlamydia 
infection 
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A productive developmental cycle of C. trachomatis strain L2 typically takes 48 
to 72 hours, and is completed with the host cell lysis or extrusion [186]. In order to 
correlate the infection level with the host cell viability, we first determined a time-point, 
where the lysis of infected host cells results in a significant decrease of the overall host 
cell viability among the sample. In addition, to validate this method as an effective 
enumeration tool for Chlamydia infection, sensitivity of the assay was examined by 
analyzing samples infected with 2-fold dilution of Chlamydia EB. The parallel samples 
were also prepared and analyzed by the conventional IFA for comparison.  
Table 2.2 summarizes the reducing capability of infected samples as well as the 
infection level determined by IFA. To statistically compare and evaluate the datasets, the 
Z’ factor was determined. The Z’ factor is a statistical parameter used to evaluate the 
quality of high-throughput assays, where Z’ factor values greater than 0.5 are indicative 
of excellent low variation and signal dynamic range [187]. At 24 hpi, the reduction 
capability of infected sample was mostly comparable to that of mock-infected cells with 
exception of the three highest inoculation doses (90.64, 92.94, and 95.77% infectivity 
determined by IFA). Given that cell lysis upon completion of developmental cycle takes 
place 48-72 hpi, this decrease at the high inoculation doses is likely to be a result of 
cytotoxicity due to over-infection, rather than completion of the developmental cycle. At 
48 and 72 hpi, the expected dose-dependent decrease in reduction capability was 
observed ranging from 108.17 to 6.90% and 105.87 to 4.21%, respectively, over 
increasing inoculation doses. The Z’ factor for 48 hpi analysis was determined to be 
above 0.5 for the three highest inoculation doses, which corresponds to 95.77 to 90.64% 
infection reported by IFA. When infection was allowed to proceed for additional 24 h,  
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Table 2.2. Comparison of IFA and alamarBlue assay for enumeration of C. trachomatis 
infection. 
 
 
 
* 1>Z-factor value ≥0.5 is indicative of an assay with suitable screening characteristics.  
Infection 
level (%) 
24 hpi, 
IFA 
Reducing capability of infected cells relative to the mock-infected cells 
 24 hpi  48 hpi  72 hpi  
 Average STDEV Z’factor  Average STDEV Z’factor  Average STDEV Z’factor  
95.77  26.40 1.36 0.56*  6.90 0.68 0.83*  4.21 0.08 0.98*  
92.94  61.80 3.66 -0.02  18.83 0.89 0.79*  6.13 0.28 0.97*  
90.64  87.84 4.71 -2.47  46.35 0.27 0.72*  13.42 1.59 0.92*  
86.70  103.00 6.16 -14.50  69.27 0.78 0.47  27.96 2.17 0.88*  
63.95  107.29 2.15 -3.74  85.86 2.26 -0.47  49.17 2.91 0.79*  
43.61  109.90 5.82 -3.60  96.11 1.15 -3.50  74.03 2.82 0.60*  
20.80  114.35 4.43 -1.88  106.17 0.42 -1.48  85.67 1.35 0.57*  
14.79  119.60 9.48 -1.88  99.23 5.43 -38.28  88.67 2.00 0.29  
7.20  114.30 0.77 -1.13  102.47 0.49 -5.27  100.06 0.72 -75.83  
3.06  108.15 8.51 -5.58  105.74 0.61 -1.76  100.58 0.47 -4.98  
2.16  102.65 4.24 -14.41  103.46 1.90 -4.71  102.67 2.49 -2.57  
1.08  120.76 8.34 -1.56  108.26 0.66 -0.94  103.06 0.50 -0.17  
0.98  109.81 0.48 -2.01  108.17 2.61 -1.67  105.87 0.66 0.31  
  R2= 0.52  R2= 0.79  R2= 0.98  
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the 7 highest inoculation doses corresponding to 95.77 to 20.80% infection level resulted 
in Z’ factor greater than 0.5, indicating that the analysis in this infection range can be 
performed with a high degree of confidence at 72 hpi. In order to utilize this assay in 
measuring infection level or assessing anti-Chlamydia activity of compounds, a sufficient 
dynamic range must be provided, and therefore, 72 hpi was chosen as the time point for 
the subsequent analysis. In addition, when a correlation coefficient (R2) was used to 
determine the degree of similarity between the two methods, linear regression analysis 
between the dataset obtained from alamarBlue assay (72 hpi) and IFA resulted in a 
correlation coefficient (R2) of 0.98, indicating a strong correlation between the two 
analyses and further supporting that enumeration of Chlamydia infection by alamarBlue 
assay is highly comparable to the conventional IFA. 
 
Validation of alamarBlue-based assay as anti-Chlamydia compound screening tool 
To begin validating this method as an anti-Chlamydia compound screening tool, 
inhibition of C. trachomatis infection by two well-established inhibitors; tetracycline 
hydrochloride and polymyxin B, was assessed [159, 162, 184]. Tetracycline is membrane 
permeable and inhibits bacterial RNA translation, whereas PMB primarily effects 
bacterial surface molecules (LPS/LOS) and perturbs membrane integrity. Chlamydia 
infection was performed to achieve approximately 90% infection in the untreated control 
sample. In both tetracycline and PMB treated samples, the compound concentration and 
reduction capability of infected cells resulted in a positive linear correlation with R2 value 
of 0.97 and 0.99, respectively (Fig. 2.7). For tetracycline, concentration range above 0.50 
µg/mL was not included in determining this linear regression since the inhibition  
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Fig. 2.7. Quantification of inhibition of C. trachomatis infection treated by 
alamarBlue assay (72 hpi).  Reduction capability of L929 cells infected with 
C .trachomatis was measured in the presence of known Chlamydia inhibitors. 
(A) polymyxin B and (B) tetracycline. Error bars indicate standard deviation of the 
triplicate infections. 
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plateaued at 0.50 µg/mL. Importantly, the plateau of reduction capability of infected cells 
at this concentration is consistent with the previously reported observation by IFA that 
0.51 µg/mL was sufficient to achieve 100% inhibition of C. trachomatis serovar L2 
[160]. Together, these data demonstrate that measuring host cell viability of infected cells 
can be used as an indirect enumeration of Chlamydia infection, as it reflected the 
infection level determined by the conventional IFA.  
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Discussion 
The lack of a tool for rapid and accurate quantification of Chlamydia infection 
suitable for a large-scale compound screening is a major challenge in the development of 
antichlamydial agents. Limited number of methods has been reported for this purpose. 
Wang et al. described an enzymatic approach using an immunofluorescence technique 
that is similar to ELISA. While this method offered a significant reduction in assay time 
compared to the traditional manual inspection, a substantial discrepancy was reported 
between the new method and the traditional manual counting of chlamydial inclusions 
due to the limited sensitivity of ImmunoSpot reader [188]. An image-based approach for 
identification and enumeration of C. psittaci infection was reported by Beeckman et al. 
[189]. This technique demonstrated automated image acquisition and automated format 
analysis; however, the number of parameters utilized by the program Image J were 
considerably fewer compared to those measured by CellProfiler. Image J identifies 
inclusions based solely on the number, surface area, and intensity of the fluorescently 
labeled spots, making it challenging to discriminate non-invasive Chlamydia aggregates 
on cell surfaces from true inclusions. In addition, these parameters require predefined 
threshold values set by investigators, resulting in limited flexibility in identification of 
subtle and complex characteristics such as those often observed among cells infected with 
Chlamydia.  
In our study, the image analysis software CellProfiler and CellProfiler Analyst 
were adapted to an automated image-based method for analysis of cell cultures infected 
with C. trachomatis. Using a customized pipeline applied to CellProfiler followed by 
machine-learning training sessions performed with CellProfiler Analyst, this automated 
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method yielded quantification of C. trachomatis infection highly comparable to the 
conventional manual inspection (Table 2.1). The suitability of this automated method as a 
large-scale application was characterized in terms of sensitivity, precision, and accuracy. 
Enumeration of a total of 72 samples infected with a dynamic range of purified EBs 
demonstrated high sensitivity of the automated method (Fig. 2.3). Low standard 
deviations among the replicates of each sample and between the aliquots demonstrated 
that the automated method was able to perform quantification of large number of samples 
with high precision. These data supported that iterative training and supervised machine-
learning, powerful features within CellProfiler Analyst, were able to accomplish highly 
specific identification of inclusions by distinguishing chlamydial inclusions from 
background staining; this has been a major challenge in previously reported automated 
approaches.  
When contrasting the two methods, one significant advantage the automatic 
method exhibited over manual enumeration was the ability to rapidly analyze large 
datasets. Analysis of a 96-well plate by the automated method, accommodating 
enumeration of 1440 images consisting approximately 130,000 cells on average per plate, 
was completed within two hours following automated image acquisition. During these 
two hours, an average hands-on time was less than 30 minutes with the rest being spent 
on computer processing. Notably, analysis of multiple 96-well plates does not require 
additional time compared to a single plate analysis. This is because regardless of the 
number of samples, only one training session is required in order to establish a 
differential rule-set, which can be applied across the entire experiment. Considering that 
manual enumeration required up to 2 minutes per field of view, equivalent analysis would 
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take up to 48 hours by the manual method. Thus, the automated method achieved 
substantial time saving in sample analysis in addition to high sensitivity and precision. 
This automated method is equally effective in analysis of small-scale (up to 
hundreds of images) or large-scale screens containing thousands of images acquired by 
automated microscopy. While analysis of hundreds of images by CellProfiler can be 
completed on a single computer in a few hours, assays described in this study consisted 
of thousands of images, and therefore more computational processing capabilities were 
required to achieve rapid analysis [190]. This challenge was addressed by utilizing a 
dedicated 'cluster' of processors (16 quad-core 2.5 GHz processors) for image processing. 
With addition of an extra module to the end of a pipeline, CellProfiler was able to 
automatically divide images into small batches and create the files containing batches of 
images [191]. Files were then submitted as individual jobs to be processed separately by 
the cluster, significantly minimizing the time required for data processing.  
In addition to the ability for accurate assessment of antichlamydial activity, this 
method may also provide insight into a possible mechanism of antichlamydial action for 
tested compounds. In this study, HEC and PMB were used as a model for the excipient 
and active ingredient component of microbicide, respectively. As anticipated, a dose-
dependent inhibitory effect was observed for both compounds. Interestingly, however, 
the pattern of inhibition over the tested range of compound concentration was uniquely 
different between the two inhibitors. The inhibitory effect of HEC exhibited direct 
proportionality to the concentration of the compound before reaching complete inhibition 
(Fig. 2.4B). In contrast, the inhibitory effect of PMB plateaued without reaching 
complete inhibition and was not proportional to compound concentration (Fig. 2.4C). 
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Therefore, it may be suggested that two compounds use different modes of inhibition 
mechanisms, and these observations could be used to begin elucidating the precise 
mechanism of inhibition (e.g. adherence, entry, etc.). It is also important to note that the 
automated method consistently reported datasets with remarkably low standard 
deviations. When compared to datasets with higher standard deviations (i.e. manually 
enumerated datasets), these datasets offer greater significance to relatively subtle 
observations such as the difference in pattern of inhibition noted between HEC and PMB.  
Whereas the image-based assay allows for detailed visualization and direct 
quantification of Chlamydia infection, IFA-based assay involves a sequence of liquid-
handling steps, which is a rate-limiting factor in this process. AlamarBlue cytotoxicity 
assay offers a simple alternative with reduced liquid handling requirements and costs 
associated with immunofluorescence-based assay. Although this method involves 72-
hour incubation time, the high-throughput capacity of a microplate reader considerably 
reduces the active time required for analysis. In addition to the ease and cost-
effectiveness, the use of host cell metabolic activity as a readout can serve a dual function 
in analysis of Chlamydia infection as well as cytotoxicity of compounds. This would be 
greatly advantageous in high-throughput screening for identification of compound with 
anti-Chlamydia activity and no host-cell toxicity. 
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Chapter III.  
In vitro Assessment of Anti-Chlamydia Properties among Polymyxin B Analogs and 
Cellulose Ether Polymers  
 
Abstract 
In the current absence of clinically approved vaccine against genital Chlamydia 
infection, vaginally delivered topical microbicides are a viable, globally applicable option 
as an alternative prevention strategy. Two main components of microbicides are the 
active ingredient with pharmacological activity against the pathogen, and the excipient, 
which is used for formulation and delivery of the active ingredient. Candidate active 
ingredients in this study are analogues of an antibiotic polymyxin B (PMB) rationally 
designed to target lipid A portion of Gram-negative LPS. Excipient candidates are 
cellulose ether polymers. These polymers are hydrophilic and have pharmaceutical 
properties that favor their use in the preparation of controlled release formulations for 
long-term administration of vaginal microbicide. Although excipients, by definition, are 
considered pharmacologically inactive ingredients, a number of studies have reported 
antimicrobial activity of excipients. In this study, anti-Chlamydia activity and 
cytotoxicity of 18 PMB analogues and 12 cellulose ether polymers were evaluated as the 
active ingredient and excipient of vaginally administered topical microbicide, 
respectively. Out of 18 PMB analogues, 14 compounds inhibited Chlamydia infection by 
greater than 60%. Interestingly, distinct structural difference was evident in the 4 
compounds without inhibitory effect on Chlamydia infection. A wide range of 
anti-chlamydial activity was observed among cellulose ether polymers.  
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Introduction 
With over 1.3 million new cases reported each year, infection due to 
C. trachomatis is the most commonly reported infection in the United States [192]. 
Although C. trachomatis infections are highly treatable with appropriate antibiotics upon 
detection, the vast majority (up to 70%) of infections in women are undiagnosed due to 
the high asymptomatic rate, and therefore progress untreated [13]. Untreated 
C. trachomatis infections can result in severe long-term consequences in women, 
including pelvic inflammatory disease (PID), ectopic pregnancy, and infertility [193]. In 
addition, C. trachomatis infections have been linked to increasing the risk of acquisition 
and transmission of HIV [194]. These concerns associated with C. trachomatis infection 
highlight the urgent need for novel preventative strategies; however, despite ongoing 
efforts, protective vaccines against Chlamydia are currently unavailable for clinical use. 
In the absence of effective vaccines, one alternative approach for prevention is the use of 
vaginally delivered topical microbicides, which offer the possibility of a 
female-controlled strategy for the prevention of sexually transmitted infections at the 
time of initial exposure.   
Topical microbicides consist of two components; the active ingredient and the 
excipient [195]. The active ingredient possesses pharmacological activity and provides 
protection against transmission of infectious agents through various mechanisms, such as 
inactivation of the pathogen or blocking specific stages of pathogenesis. The excipients 
are pharmacologically inert delivery vehicles that allow uniform distribution of the active 
ingredient while ensuring product stability and appropriate pH in vaginal mucosa [196]. 
Excipients can be categorized into a number of groups including gelling agents, 
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preservatives, solvents, antioxidants [197]. One of the key challenges in the development 
of topical microbicide is identifying compounds that hold the potential to be effective 
against the disease causing pathogens while causing minimal or no adverse effect upon 
long-term repeated usage.  
The active ingredient candidates in this study are a series of rationally designed 
compounds, developed by David and colleagues, targeting LPS of Gram-negative 
bacteria for therapeutic options against septic shock caused by LPS (endotoxin) [198-
200] (Fig. 3.1). In order to sequester and neutralize endotoxins, small molecules were 
developed targeting lipid A, the biologically active and toxic moiety of LPS, which is 
structurally highly conserved among Gram-negative bacteria [198-200] (Fig. 1.3). 
Lipid A is anionic and amphiphilic, and allows interaction with a variety of cationic 
hydrophobic ligands [201]. Polymyxin B (PMB), a cationic peptide antibiotic isolated 
from Bacillus polymyxa [202] (Fig. 3.2 A), is well known to bind lipid A and neutralize 
the endotoxicity in vivo and in vitro [203-205]. However, the demonstrated toxicity of 
PMB in eukaryotic cells limits its use in therapy or prophylaxis [206]. In search for non-
toxic PMB analogues with potency comparable to that of PMB, an NMR-derived model 
of PMB-lipid A complex [207] (Fig. 3.2 B), as well as in vitro activity studies were 
utilized to define and validate the crucial pharmacophore for optimal recognition and 
neutralization of lipid A [200]. Base on these findings, small molecule analogues of PMB 
were rationally designed and synthesized. As reviewed in preceding chapter (Chapter I. 
Introduction: Chlamydia lipooligosaccharide), chlamydial LOS shares highly conserved 
bis-phosphorylated glucosamine backbone of lipid A with E. coli LPS. Given that PMB 
interacts with LPS through this lipid A backbone structure, it is expected that similar  
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Fig. 3.1. Structures of polymyxin B (PMB) analogues. In search for non-toxic PMB 
analogues with potency comparable to that of PMB, 18 PMB analogues were 
rationally designed based on the crucial pharmacophore for optimal recognition and 
neutralization of lipid A determined from the NMR-derived model of PMB-lipid A 
complex and in vitro activity studies. 
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Fig. 3.2. A NMR-derived model of the PMB-lipid A complex (adapted from Sil et 
al. [198]).  (A) Structure of PMB. (B) A NMR-derived model. PMB is in stick 
representation with van der Waals surface, and lipid A is displayed in ball-and-stick 
representation. Salt bridges (dotted lines) are proposed to occur between each 
phosphate group on lipid A and two pairs of the NH2 groups of PMB [207].  
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interaction would take place between PMB and chlamydial LOS. Therefore, it was 
hypothesized that PMB analogues designed for neutralization of E. coli LPS would bind 
to chlamydial LOS and potentially exhibit inhibitory effects on Chlamydia infection by 
modifying the function of LOS crucial during the developmental cycle.  
The excipient candidates in this study are cellulose ether polymers commonly 
used in vaginal gels [208] (Table 3.1). Hydroxyethyl cellulose (HEC), 
hydroxypropylmethyl cellulose (HPMC), methylcellulose (MC), and sodium 
carboxymethylcellulose (NaCMC) are cellulose ethers that differ in their substitution type, 
as well as degree of substitution (DS) and molar substitution (MS) (Fig. 3.3). The degree 
of substitution is defined as the average number of hydroxyl groups substituted per 
anhydroglucose unit, whereas the molar degree of substitution is defined as the average 
number of moles of substituent per anhydroglucose unit.  
The cellulose ether polymers are hydrophilic and have pharmaceutical properties 
that favor their use in the preparation of controlled release formulations [209]. By 
definition, excipients are typically chosen from compounds with no pharmacological 
activity, and therefore lack any therapeutic properties. However, a number of studies 
have reported antichlamydial activity of excipients in vitro [197, 210, 211]. Specifically, 
HEC was demonstrated to be inhibitory against C. trachomatis infection of HeLa 229 
cervical epithelial cells [211]. Excipient compounds that possess inhibitory effect against 
C. trachomatis would be beneficial as they can potentially enhance the overall efficacy of 
antichlamydial microbicide when used concomitantly with the active ingredient. As 
importantly, considering the use of cellulose ether polymers as “inactive” excipients in 
vaginal microbicides, it is critical to ensure the compounds do not contribute to increased  
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Table 3.1. Cellulose ether polymers 
  Source MW (kDa) DSa MSb 
HEC Hydroxyethyl cellulose     
 HEC-1 Sigma-Aldrich 1,300 1.5 2.5 
 HEC-2 Sigma-Aldrich 90 1.5 2.5 
 HEC-3 Sigma-Aldrich 250 1.0 2.0 
 Natrosol Hercules/Aqualon  1,000  1.5 2.5 
NaCMC Sodium carboxymethylcellulose     
 NaCMC-4 Sigma-Aldrich 250 0.9 NA 
 NaCMC-5 Sigma-Aldrich 250 1.2 NA 
 NaCMC-7HF Hercules/Aqualon  700 0.7 NA 
HPMC Hydroxypropylmethyl cellulose      
 HPMC-7 Sigma-Aldrich 10 1.8-2.0 0.2-0.3 
 HPMC-8 Sigma-Aldrich 86 1.8-2.0 0.2-0.3 
 HPMC-9 Dow Chemical  86 1.8 0.13 
MC Methylcellulose     
 MC-6 Sigma-Aldrich 40 1.6-1.9 NA 
 MC-A4M Dow Chemical  86 1.8 NA 
 
a. Degree of substitution (DS) = the average number of hydroxyl groups replaced by the substituents per 
anhydroglucose ring unit of cellulose  
b. Molar substitution (MS) = the average number of moles of substituents per anhydroglucose ring unit of 
cellulose  
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Fig. 3.3. Structure of cellulose ether polymers. (A) Structure of anhydroglucose 
units of cellulose. R denotes the substituents to the anhydroglucose unit. (B) The 
substituents for HEC (hydroxyethyl cellulose), NaCMC (sodium 
carboxymethylcellulose), HPMC (hydroxypropylmethyl cellulose), and MC 
(methylcellulose). 
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infection susceptibility by cytotoxicity or other mechanisms. In vitro susceptibility of 
C. trachomatis to 18 PMB analogues and 12 cellulose ether polymers were evaluated to 
be considered as the active ingredient and the excipient component of vaginally-delivered 
microbicide, respectively.  
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Materials and Methods 
Bacteria and cell culture  
C. trachomatis lymphogranuloma venereum (LGV) serovar L2/434/Bu EBs were 
purified from infected L929 cells using a 30% Renografin density gradient and stored in 
sucrose phosphate glutamate (SPG) at -80°C until use, as previously described [177]. 
L929 cells were routinely cultured in RPMI 1640 culture medium (Mediatech, Inc., 
Manassas, VA) supplemented with 5% fetal bovine serum (FBS) (Thermo Fisher 
Scientific, Liverpool, NY) and 10 µg/mL gentamycin (MP Biomedicals, Santa Ana, CA) 
at 37°C in a humidified atmosphere of 5% CO2. 
 
Compounds preparation  
 PMB analogues were obtained in powder form and dissolved in 100% DMSO to 
1 mM. Each compound was serially diluted to appropriate concentrations in HBSS. 
Hydroxyethyl cellulose (HEC), sodium carboxymethylcellulose (NaCMC), 
hydroxypropylmethyl cellulose (HPMC), and methylcellulose (MC) were obtained in 
powder. The source, molecular weight, degree of substitution (DS), and molar 
substitution (MS) for each compound are summarized in Table 3.1. Each cellulose ether 
compound was dissolved in HBSS to appropriate concentrations, vortexed to ensure 
homogeneity, and stored overnight at 4°C to allow hydration of the polymers. Each 
polymer solution was adjusted to pH 7.4. 
 
AlamarBlue cytotoxicity assay 
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L929 mouse fibroblast cells were plated in a 96-well plate (Bioexpress, Kaysville, 
UT) at density of 7 x 104 cells/mL, 200 µL/well, and incubated overnight. Microbicide 
candidate compounds were serially diluted in RPMI 1640 culture to the appropriate 
concentrations. Culture medium was removed and 200 µL/well of fresh medium 
containing the tested compound was added to a monolayer of cells. The plates were 
incubated at 37 °C for 18 h. Following the incubation period, culture medium was 
removed from the cells and 200 µL of RPMI 1640 culture medium without phenol red 
containing 10% (v/v) alamarBlue reagent (Life Technologies, Grand Island, NY) was 
added. The absorbance was measured in a PowerWave microplate spectrophotometer 
(BioTek, Winooski, VT) at 570 nm (reduced) and 600 nm (oxidized) with KC4 data 
collection and analysis software (BioTek, Winooski, VT) after 8 h. The results were 
expressed as the percentage of alamarBlue reduced by cells in the presence of DS-96 
relative to alamarBlue reduced by control cells in the absence of the compound, using a 
formula provided by the manufacture: x100, where εox = molar 
extinction coefficient of alamarBlue oxidized form, εox = molar extinction coefficient of 
alamarBlue reduced form, A = absorbance of test wells, A’ = absorbance of positive 
control well (mock-infection), λ1  = 570 nm, and λ2= 600 nm.   
 
Chlamydia infection and inhibition assays 
Purified C. trachomatis L2 EBs were diluted to the appropriate concentrations in 
Hank’s Buffered Salt Solution (HBSS, Mediatech, Inc., Holly Hill, FL). Microbicide 
candidate compound or DMSO as a mock-treatment control was diluted in either HBSS 
€ 
(εox )λ2Aλ1 − (εox )λ1Aλ2
(εox )λ2A'λ1 − (εox )λ1A'λ2
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containing diluted EBs to the appropriate concentrations, according to treatment types. 
Bacteria and compound were incubated for an hour at room temperature for pre-
treatment. Following an hour, the mixtures were added to a monolayer of cells. Cells 
were inoculated at room temperature for 2 h. After the inoculation period, cells were 
washed once with HBSS, fresh culture medium without compounds was added, and 
incubated at 37°C in an atmosphere of 5% CO2. Twenty-four hours post infection (hpi), 
cells were washed once with HBSS and fixed with 100% methanol for 10 minutes at 
room temperature. Samples were kept in phosphate buffered saline (PBS) at 4°C until the 
time of analysis.  
 
Immunofluorescence microscopy  
Following fixation, samples were stained with MicroTrack C. trachomatis culture 
confirmation test (Syva Co., Palo Alto, CA) diluted to 1:40 in PBS for an hour in the 
dark, followed by a 5 min stain with 1 µg/mL DAPI in PBS. DAPI was removed and 
90% (v/v) glycerol in PBS was added to prevent rapid fading of fluorescence during 
analysis. Plates were stored in the dark at 4°C until imaging. Images were captured and 
analyzed using CellProfier and CellProfiler Analyst (CP/CPA) as described in the 
preceding chapter (Chapter II. Development and Validation of Novel Analysis Methods 
for Chlamydia Infection).  
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Results and Discussion 
Cytotoxicity of PMB analogues in mouse L929 fibroblast cells 
Due to the obligate intracellular nature of Chlamydia, it is also important to 
ensure that inhibition of Chlamydia growth is a direct result of disruption of chlamydial 
factor rather than toxicity to the host cell. Since the PMB analogues had not been studied 
in cell culture previously, cytotoxicity of the compounds on L929 cells was assessed prior 
to evaluating the inhibitory effect to determine appropriate working concentrations. The 
metabolic activity of the host cell was quantitatively analyzed using alamarBlue 
cytotoxicity assay following exposure to each compound. The standard procedure for 
Chlamydia infection of cell culture consists of 2-hour infection of the host cell monolayer 
followed by the removal of bacteria and incubation of infected cells at 37 °C until the 
time of analysis 24 hpi. Therefore, monolayers of L929 cells were incubated with serially 
diluted PMB analogues for 2 h, and the metabolic capability of the compounds was 
measured following 24 h incubation at 37 °C. A broad concentration range (0.24-100 
µM) was tested, followed by several rounds of analysis to narrow the concentration range 
(data not shown). An appropriate working concentration, defined as the highest 
concentration at which the reducing capability of the cells exposed to a compound was 
greater than 80% relative to DMSO control, was determined for each PMB analogue 
compound (Fig. 3.4).  
 
Anti-Chlamydia activity of PMB analogues in mouse L929 fibroblast cells 
 To examine the effect of PMB analogues on Chlamydia infection, L929 cells 
were infected with C. trachomatis in the presence of the compounds, and infection level  
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Fig. 3.4. Cytotoxicity analysis of PMB analogues. Metabolic activity of L929 cells 
were measured by alamarBlue redox indicator following 2h incubation with each PMB 
analogue. A working concentration for each compound, as defined as the highest 
concentration at which the metabolic activity of the host cell resulted in greater than 
80% of the control sample, is indicated on the x-axis. Reducing capability of samples 
treated with the compounds relative to untreated control samples were determined 
after 24 h incubation.  
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was enumerated 24 hpi. Considering the rational design of PMB analogues, possible 
inhibitory effect is expected to be through interaction with chlamydial surface that is 
mediated by the affinity for LOS. For this reason, highly purified C. trachomatis EBs 
were pre-treated with each analogue for an hour prior addition to the host cell to allow 
sufficient time to interact with the bacterial surface. Each analogue was tested at the 
working concentration previously determined using alamarBlue cytotoxicity assay.  
Out of 18 analogues, 14 analogues resulted in inhibition of intracellular 
Chlamydia growth by greater than 60%, and 12 of which inhibited infection by greater 
than 85% (Fig. 3.5). Interestingly, the four analogues with no inhibitory activity (DS-321, 
DS-322, DS-368, and DS-388) share apparent structural similarities (Fig. 3.1). One of the 
major structural features shared among these four analogues is a higher degree of 
substitution on amines, which is absent in the analogues with inhibitory activity. This 
structure-activity correlation, not surprisingly, was in agreement with the previously 
defined structural requirements for optimal recognition of lipid A [200]. It has been 
demonstrated that binding of a PMB analogue to lipid A requires the simultaneous 
interaction of two protonatable amine functions on the analogues with the negatively 
charged phosphates on lipid A [200]. Whereas most of the PMB analogues contain 
primary terminal amines and secondary nonterminal amines, four analogues without 
anti-Chlamydia activity contain secondary terminal amines and tertiary nonterminal 
amines. This suggests a possibility that bulky substitutions at these amines may sterically 
hinder the interaction between the analogue and lipid A, and result in the absence of 
inhibitory activity.   
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Fig. 3.5. Inhibition of C. trachomatis infection by PMB analogues. C. trachomatis 
EBs were treated with a PMB analogue or DMSO (mock-treatment) for an hour prior 
to infection. L929 cells were infected with pre-treated EBs and cultured for 24 h. 
Infected cultures were fixed with methanol and immunofluorescently stained 24 hpi. 
Chlamydia growth was quantified using the image-based automated enumeration 
method described in Chapter II. Percent inhibition was calculated based on the number 
of inclusion positive cells in DS-96 treated samples relative to DMSO treated samples.  
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Further activity study and structural optimization will be necessary for higher 
potency, minimum cytotoxicity, and effectiveness in animal challenge studies. 
Nonetheless, it is important to note that PMB analogues appear to target Chlamydia LOS 
in a similar manner to E. coli LPS, and effectively inhibit Chlamydia infection in cell 
culture at relatively low concentrations without apparent cytotoxicity. 
 
Cytotoxicity and Anti-Chlamydia activity of cellulose ether polymers 
 Water-soluble cellulose ether polymers are often used in a broad variety of 
industrial application including many pharmaceutical products formulated with cellulose 
ethers [209]. Although cellulose ethers are known to be non-toxic in animals, it is still 
crucial to perform cytotoxicity assay in tissue culture, as the lack of toxicity in animals 
may not always translate into cell culture cytotoxicity. As cellulose ether polymers 
readily dissolve in water to form viscous solution, one of the experimental challenges 
presented by these polymers is the ability for accurate pipetting. Therefore, all 
compounds were diluted in buffer until the viscosity of the polymer was in such that 
accurate pipetting could be achieved. Once working concentrations were determined, 
alamarBlue assay was performed to ensure that the polymers had no cytotoxic properties 
on the host cells at these concentrations (Fig. 3.6).   
 Since the cellulose ether polymers are viscous in nature, it was crucial to ensure 
that the inhibitory effect is not a result of the physical barrier, where the viscosity simply 
limits access of EBs to the host cell surface. Ideally, the working concentration of 
polymers should be standardized based on the factors such as viscosity and buoyant 
density of EBs in each polymer solution. In the absence of these studies, polymer  
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Fig. 3.6. Cytotoxicity analysis of cellulose ether polymers. Metabolic activity of 
L929 cells were measured by alamarBlue redox indicator following 2h incubation with 
each cellulose ether polymer diluted to the concentration with no apparent viscosity. 
Reducing capability of samples treated with the compounds relative to untreated 
control samples were determined after 24 h incubation. Error bars indicate standard 
deviation of the duplicate wells. 
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solutions were diluted until no longer viscous. C. trachomatis EBs were pre-treated with 
each of the polymers prior to infection and the growth of Chlamydia was analyzed 24 hpi. 
Although none of the polymers exhibited inhibitory activity as high as HEC-2, 90 kDa 
HEC previously shown to have anti-Chlamydia activity, all but one polymers (HPMC-7) 
exhibited greater than 20% inhibition in Chlamydia growth (Fig. 3.7). Inhibition levels 
were 26.1 to 95.6% for hydroxyethyl cellulose, 25.2 to 50.8% for sodium 
carboxymethylcellulose, 3.9 to 48.8% for hydroxypropylmethyl cellulose, and 19.5 to 
33.3% for methylcellulose. No correlation was evident between the inhibitory activity 
and the degree of substitution, molar substitution, or molecular weight. How the 
cellulose-ether polymers inhibit Chlamydia infection remains to be determined. However, 
as reviewed in Chapter I, polysaccharides are thought to play a crucial role in the 
interaction of Chlamydia and the host cell surface in the initial stages of the 
developmental cycle. Therefore, it is possible that cellulose ether polysaccharide acts as 
competitive inhibitors for chlamydial adhesion. 
 
Combined use of DS-96 with HEC results in synergistic effect 
In the future animal challenge model for microbicide evaluation, the active 
ingredient candidates will likely require formulation into a gel suitable for topical 
application. When multiple compounds are applied together, the effect of one compound 
can depend on the presence or absence of the other compound. Such interactions between 
compounds are classified as additive, synergistic, or antagonistic depending on whether 
their combined effect is equal to, greater than, or less than expected, based on the activity 
of the individual compounds [212]. DS-96 and HEC-2, both of which exhibited high  
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Fig. 3.7. Susceptibility of C. trachomatis to cellulose ether polymers. 
C. trachomatis EBs were treated with a cellulose ether polymer or buffer (mock-
treatment) for an hour prior to infection. L929 cells were infected with pre-treated EBs 
and cultured for 24 h. Infected cultures were fixed with methanol and 
immunofluorescently stained 24 hpi. Chlamydia growth was quantified using the 
image-based automated enumeration method described in Chapter II. Percent 
inhibition was calculated based on the number of inclusion positive cells in DS-96 
treated samples relative to DMSO treated samples.  
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inhibitory property against C. trachomatis, were used to examine possible additive, 
synergistic, or antagonistic effects of the combined used an active ingredient and an 
excipient candidate.  
EBs were pre-treated with the mixture of DS-96 and HEC at concentrations where 
their inhibitory effects are expected to be at low level (<50%) when used individually 
(Fig. 3.8). When EBs were pre-treated with HEC (0.0875 to 0.35%) alone, a low level of 
inhibition was observed in a dose-dependent manner (18.1 to 43.2%). Similarly, DS-96 (1 
µM) alone resulted in 41.5% inhibition. Interestingly, when EBs were pre-treated with a 
mixture of 1 µM DS-96 and 0.0875% HEC, Chlamydia growth was inhibited by 98.8%, 
indicating that synergistic effect exists between the two compounds because the 
combined use of DS-96 and HEC resulted in inhibition on Chlamydia growth greater than 
the sum of the effects of the individual compound. Whether other combinations of a PMB 
analogue and an excipient result in similar synergy remains to be examined. Nonetheless, 
this is an intriguing observation that will require further investigation to understand the 
underlying mechanism of synergy. 
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Fig. 3.8. Synergistic effect of 90 kDa HEC and DS-96 on C. trachomatis infection. 
Effect of the combined use of 90 kDa HEC and DS-96 was examined. EBs were pre-
treated with HEC (0.085, 0.175, 0.35 %) or DS-96 (1 µM) alone, or the two 
compounds combined. Chlamydia growth was enumerated 24 hpi. Percent inhibition 
of Chlamydia growth was calculated relative to DMSO-mock treated sample. Error 
bars indicate standard deviation of the triplicate samples.      
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Chapter IV.  
Lipopolysaccharide-binding Alkylpolyamine DS-96 Inhibits Chlamydia trachomatis 
Infection by Blocking Chlamydia Attachment and Entry 
 
Abstract 
The small molecule DS-96, rationally designed for high affinity to E. coli lipid A, 
was previously demonstrated to bind and neutralize LPS from a wide variety of Gram-
negative bacteria. Aside from the lack of the repeating O-antigen, chlamydial 
lipooligosaccharide (LOS) shares the general molecular architectures with E. coli LPS. 
Importantly, the portion of lipid A, where the interaction with DS-96 is expected to take 
place is well-conserved between the two organisms, leading to a hypothesis that DS-96 
inhibits Chlamydia infection by binding to LOS and compromising the function. In this 
study, anti-chlamydial activity of DS-96 was examined in cell culture. DS-96 inhibited 
the intercellular growth of Chlamydia in a dose-dependent manner and offered a high 
level of inhibition at a relatively low concentration (8 µM). The data also revealed that 
infectious EBs were predominantly blocked at the attachment step, as indicated by the 
reduced number of EBs associated with the host cell surface following the pre-treatment. 
Of those EBs that were capable of attachment, the vast majority was unable to gain entry 
into the host cell. Inhibition of EBs attachment and entry by DS-96 suggests that 
Chlamydia LOS may be critical to these processes during the developmental cycle. 
Importantly, given the low associated host toxicity, DS-96 is expected to perform well in 
animal studies as an active compound in a vaginal microbicide. 
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Introduction 
Blocking infection in an early stage of pathogenicity (i.e. adherence and entry) 
before bacteria gain access to the host is a desirable preventive approach, as often 
evidenced in the efforts to produce sterile immunity in vaccine development. Bacterial 
surface molecules are potential targets for this purpose because they generally play 
essential roles in establishing a productive infection. One such molecule is 
lipopolysaccharide (LPS) of Gram-negative bacteria. LPS is a major constituent of the 
outer membrane and plays a crucial role for the survival of the organisms by maintaining 
the membrane integrity and providing a permeability barrier [140, 213, 214]. LPS has 
also been suggested to play a role in bacterial adhesion as well as being a prominent 
virulence determining factor for several Gram-negative organisms, and thus may be a 
potential target molecule in the development of antimicrobial agents [141-144]. 
The small molecule DS-96, a synthetic alkylpolyamine, was previously developed 
to neutralize endotoxicity of LPS in the pathogenesis of Gram-negative septic shock (Fig. 
4.1A) [198]. The molecule was rationally designed based on an NMR-derived model of 
the interaction between E. coli LPS and the antibiotic polymyxin B (PMB) [198, 200, 
215, 216]. The cationic polypeptide antibiotic PMB is well known for the ability to bind 
to and neutralize the anionic lipid A moiety, which elicits strong immune response when 
present in systemic circulation [182]. The pharmacophore necessary for optimum binding 
and neutralization of LPS was determined through the model and used to synthesize 
various polycationic amphiphiles with a spermine backbone, and eventually led to the 
discovery of a novel alkylpolyamine DS-96 [198]. In their study, DS-96 was  
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Fig. 4.1. DS-96 exhibits inhibition of C. trachomatis infection in a dose-dependent 
manner. (A) Structure of DS-96. (B) C. trachomatis EBs were treated with varying 
concentrations of DS-96 (0-16 µM) or DMSO (mock-treatment) for an hour prior to 
infection. L929 cells were infected with pretreated EBs and cultured for 24 h. Infected 
cultures were fixed with methanol 24 hpi. Chlamydia was stained with anti-MOMP 
antibody (green) and host cells were counterstained with DAPI (nuclei, blue) and 
Evan’s Blue  (cytoplasm, red). (C) Inhibition of inclusion formation among the 
samples treated with various concentration of DS-96 was quantified 24 hpi using the 
automated image-based enumeration method (32). Percent inhibition was counted 
based on the number of inclusion positive cells in DS-96 treated samples relative to 
DMSO treated samples. Error bars indicate standard deviation of the triplicate 
samples.  
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demonstrated to bind to LPS with high affinity and neutralize LPS endotoxicity of a 
variety of Gram-negative bacteria with potency indistinguishable from that of PMB 
[198]. Importantly, daily administration of DS-96 at concentrations ten-fold higher than 
the fully protective dose resulted in no detectable toxicity in a mouse study [198]. In 
Chlamydia, PMB treatment of the organism has been demonstrated to significantly 
decrease infectivity in cell culture infection [152, 217, 218], and also to impair the 
bacterial membrane integrity [219]. Despite its effectiveness, clinical use of unmodified 
PMB is limited due to the associated side effects on the eukaryotic hosts [220].  
C. trachomatis, like many other nonenteric mucosal pathogens, possesses 
lipooligosaccharide (LOS) rather than LPS in their outer membrane. Chlamydial LOS 
differs from a typical LPS in that it consists of a trisaccharide core of 3-deoxy-D-manno-
2-octulopyranosylonic acid (Kdo) rather than disaccharide in LPS and lacks the repeating 
O-antigen polysaccharide side chain, which is similar to a rough enterobacterial LPS 
[146]. Nonetheless, LOS and LPS share a conserved bis-phosphorylated glucosamine 
backbone of lipid A at which interaction with PMB takes places. In contrast to enteric 
bacteria, chlamydial lipid A has been shown to exhibit low endotoxicity, reportedly due 
to the fewer number of hydrocarbon and the longer chain length [147, 148]. In addition, 
while LPS is an important structural component for the membrane integrity of 
Gram-negative bacteria, the outer membrane of the infectious, extracellular form of 
Chlamydia is highly disulfide cross-linking of cysteine-rich proteins. This rigid outer 
membrane is expected to provide structural rigidity and stability [149, 150]. To date, 
relatively few studies have been reported addressing the biological significance of 
chlamydial LOS in the unique bi-phasic developmental cycle of Chlamydia.  
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The developmental cycle of Chlamydia begins with the attachment of the 
infectious but metabolically inert elementary body (EB) to the surface of non-phagocytic 
epithelial cells. This attachment involves a two-step process with the initial reversible 
electrostatic interaction with glycosaminoglycan, followed by a more specific irreversible 
binding to putative cell surface receptors [221]. Following the attachment, the EB induces 
its own uptake by initiating a signal transduction cascade of the host cell that leads to 
recruitment and reorganization of the actin cytoskeleton at the site of attachment [222]. 
Once inside the host cell, the EB converts into a larger metabolically active reticulate 
body (RB), which replicates by binary fission within a membrane bound vacuole, termed 
inclusion. After several rounds of replication, RBs transform back to EBs and are 
released by host cell lysis or extrusion [186].  
Recently, Nguyen et al. demonstrated the crucial role of chlamydial LOS in 
proper conversion of RBs into EBs, using small molecule inhibitors of the lipid A 
biosynthesis pathway [151]. In contrast, little effect on the organism’s replication was 
observed in the presence of the inhibitor. However, since the inhibitors of LOS 
biosynthesis do not have inhibitory effect on the pre-formed LOS, the possible role of 
LOS during early stages of the developmental cycle of Chlamydia remains to be 
examined. 
Given the demonstrated high affinity of DS-96 for LPS of other Gram-negative 
bacteria and conserved structural features between LPS and chlamydial LOS, it was 
hypothesized that DS-96 inhibits Chlamydia infection by binding to the lipid A moiety 
and compromising the function of LOS that is crucial during the developmental cycle. To 
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study this hypothesis, inhibitory activity of DS-96 during various stages of 
C. trachomatis infection was examined in cell culture.  
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Materials and Methods 
Bacteria, cell culture, and compound 
C. trachomatis lymphogranuloma venereum (LGV) serovar L2/434/Bu EBs were 
purified from infected L929 cells using a 30% Renografin density gradient and stored in 
sucrose phosphate glutamate (SPG) at -80°C until use, as previously described [177]. 
L929 cells were routinely cultured in RPMI 1640 culture medium (Mediatech, Inc., 
Manassas, VA) supplemented with 5% fetal bovine serum (FBS) (Thermo Fisher 
Scientific, Liverpool, NY) and 10 µg/mL gentamycin (MP Biomedicals, Santa Ana, CA) 
at 37°C in a humidified atmosphere of 5% CO2. DS-96 was a kind gift from Dr. Sunil 
David (University of Kansas). DS-96 was obtained in powder form, dissolved in DMSO 
to the stock concentration of 1 mM, and stored at 4°C.  
 
AlamarBlue cytotoxicity assay 
L929 mouse fibroblast cells were plated in a 96-well plate (Bioexpress, Kaysville, 
UT) at density of 7 x 104 cells/mL, 200 µL/well, and incubated overnight. DS-96 was 
serially diluted in RPMI 1640 culture medium containing.  Culture medium was removed 
from the 96-well plate culture and 200 µL/well of fresh medium containing various 
concentration (0.5-128 µM) of DS-96 was added. The plates were incubated at 37 °C for 
18 h. Following the incubation period, culture medium was removed from the cells and 
200 µL of RPMI 1640 culture medium without phenol red containing 10% (v/v) 
alamarBlue reagent (Life Technologies, Grand Island, NY) was added. The absorbance 
was measured in a PowerWave microplate spectrophotometer (BioTek, Winooski, VT) at 
570 nm (reduced) and 600 nm (oxidized) with KC4 data collection and analysis software 
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(BioTek, Winooski, VT) after 8 h. The results were expressed as the percentage of 
alamarBlue reduced by cells in the presence of DS-96 relative to alamarBlue reduced by 
control cells in the absence of the compound, using a formula provided by the 
manufacture: x100, where εox = molar extinction coefficient of 
alamarBlue oxidized form, εox = molar extinction coefficient of alamarBlue reduced 
form, A = absorbance of test wells, A’ = absorbance of positive control well (mock-
infection), λ1  = 570 nm, and λ2= 600 nm.   
 
Chlamydia infection and inhibition assays 
Purified C. trachomatis L2 EBs were diluted to the appropriate concentrations in 
Hank’s Buffered Salt Solution (HBSS, Mediatech, Inc., Holly Hill, FL). DS-96 or DMSO 
as a mock-treatment control was diluted in either HBSS alone or HBSS containing 
diluted EBs to the appropriate concentrations, according to treatment types. The mixtures 
of bacteria and compound were incubated for an hour at room temperature. Following an 
hour, the mixtures were added to a monolayer of cells. Cells were inoculated at room 
temperature for 2 h. For the centrifugation-assisted inoculation, the cells were centrifuged 
at 900 x g for 1 h. After the inoculation period, cells were washed once with HBSS, fresh 
culture medium was added, and incubated at 37°C in an atmosphere of 5% CO2. For the 
treatment of host cells, diluted DS-96 or DMSO in HBSS containing no bacteria were 
transferred to ~70% confluent L929 cell monolayers and incubated for an hour at room 
temperature. Following the incubation period, the compound was removed, cells were 
washed and inoculated with the diluted bacteria. For the time-course treatment, bacteria 
were pre-treated, or DS-96 was added to culture medium at the indicated time period. 
€ 
(εox )λ2Aλ1 − (εox )λ1Aλ2
(εox )λ2A'λ1 − (εox )λ1A'λ2
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Twenty-four hours post infection (hpi), cells were washed once with HBSS and fixed 
with 100% methanol for 10 minutes at room temperature. Samples were kept in 
phosphate buffered saline (PBS) at 4°C until the time of analysis.  
 
Immunofluorescence microscopy  
Following fixation, samples were stained with MicroTrack C. trachomatis culture 
confirmation test (Syva Co., Palo Alto, CA) diluted to 1:40 in PBS for an hour in the 
dark, followed by a 5 min stain with 1 µg/mL DAPI in PBS. DAPI was removed and 
90% (v/v) glycerol in PBS was added to prevent rapid fading of fluorescence during 
analysis. Plates were stored in the dark at 4°C until imaging. Samples were visualized 
using Olympus ix71 inverted fluorescence microscope (Center Valley, PA) with a 40X 
objective with 0.55 numerical aperture. Images were captured using a QImaging QICAM 
digital camera 12-bit Mono Fast 1394 Cooled camera and QCapture Suite software 
version 3.1.3.5 (QImaging Corp., Surrey, BC  Canada). Image-based automated 
quantification using CellProfier and CellProfiler Analyst (CP/CPA) was performed as 
described previously [223]. 
 
Antibody staining of C. trachomatis EBs  
For staining of C. trachomatis EBs with anti-LOS antibody, EBs were incubated 
with 8 µM DS-96 or the equivalent dilution of DMSO for control at room temperature for 
pre-treatment. After 1 h, 300 µL of the treated bacteria were transferred into 8-well µ-
chamber slides (ibidi, Verona, WI). Bacteria were allowed to settle and adhere to the 
bottom of the plate at room temperature for 1 h. The liquid was aspirated and bacterial 
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samples were fixed with 100% methanol for 10 min. For immunofluorescence staining, 
one set of samples were stained with monoclonal anti-LOS antibody (ViroStat, Cat# 
1683)  diluted 1:500 in PBS at room temperature for 1 h and counterstained with 1 µg/mL 
DAPI in PBS for 5 min. A parallel set of samples was stained with primary goat anti-
MOMP antibody (ViroStat, Cat# 1621) diluted 1:500 in PBS for an hour, followed by a 
5 min stain with 1 µg/mL DAPI in PBS. Samples were viewed with Olympus ix71 
inverted fluorescence microscope (Center Valley, PA) with a 40X objective with 0.55 
numerical aperture. Images were captured using QImaging QICAM digital camera 12-bit 
Mono Fast 1394 Cooled camera and QCapture Suite software version 3.1.3.5 (QImaging 
Corp., Surrey, BC  Canada).  
 
Attachment assay  
Purified C. trachomatis L2 EBs were diluted in HBSS and DS-96 was added to a 
final concentration of 8 µM for pre-treatment of the bacteria for an hour at room 
temperature.  An equivalent dilution of DMSO mock-treatment was used as a negative 
control and 500 µg/mL heparan sulfate (HS) was used as a positive control for 
chlamydial attachment. L929 cells were inoculated with compound-treated EBs and 
incubated at 4 °C for an hour. Following inoculation, cells were washed three times with 
cold HBSS to remove nonspecifically bound EBs, fixed with 100% methanol, and stained 
with MicroTrack C. trachomatis culture confirmation kit. Images were captured using 
SlideBook (Intelligent Imaging Innovations, Inc., Denver, CO) software and Olympus 
IX81 inverted microscope (Center Valley, PA) equipped with a 1.45 numerical aperture 
oil-immersion 100X objective and Hamamatsu EM-CCD camera. 
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Entry assay 
Purified C. trachomatis L2 EBs were diluted in HBSS and incubated with 8 µM 
DS-96 at room temperature for an hour for pre-treatment. An equivalent dilution of 
DMSO mock-treatment was used as a negative control. The inocula were added to L929 
cells and incubated for 2 h at room temperature. Following the incubation period, the 
inocula were removed, cells were washed, and fresh culture media were added. Infected 
cells were incubated at 37 °C for 3 h to allow sufficient time for bacterial attachment and 
entry. At 3 hpi, culture medium was removed and cells were washed once with PBS. 
Differential staining was performed to distinguish the bacteria that remained extracellular 
from those that gained entry into the host cells. To stain the extracellular bacteria, the 
cells were incubated with primary goat anti-MOMP antibody diluted 1:500 in PBS 
(ViroStat, Cat# 1621) for an hour at room temperature prior to permeabilization of host 
cells. The cells were washed three times with PBS, fixed and permeabilized with 100% 
methanol for 10 min at room temperature. The cells were washed once with PBS to 
remove methanol and incubated with secondary donkey anti-goat Alexa Fluor 568 
(Invitrogen, Carlsbad, CA) at 1:1000 dilution for an hour. Following three washes with 
PBS, the cells were incubated with primary mouse anti-Chlamydia antibody (Abcam, 
Cat# ab21019) diluted 1:500 for an hour at room temperature, washed three times with 
PBS, and incubated with secondary goat anti-mouse Alexa Fluor 488 (Invitrogen, 
Carlsbad, CA). Following three washes with PBS, cells were incubated with 1 µg/mL 
DAPI in PBS for 5 min to label host cell nuclei. Images were captured using SlideBook 
(Intelligent Imaging Innovations, Inc., Denver, CO) software and Olympus IX81 inverted 
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microscope (Center Valley, PA) equipped with a 1.45 numerical aperture oil-immersion 
100X objective and Hamamatsu EM-CCD camera. 
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Results 
DS-96 inhibits Chlamydia infection in a dose-dependent manner  
To begin examining the effect of DS-96 on Chlamydia infection, 
C. trachomatis L2 EBs were pre-treated with various concentrations of the compound 
ranging 0 to 16 µM. The standard procedure for Chlamydia infection of cell culture 
consists of 2-hour infection of eukaryotic the cell monolayer at room temperature to 
facilitate attachment. This is followed by washing to remove unbound bacteria and 
placement at 37 °C to fully enable chlamydial entry. In the inhibition assay, EBs were 
pre-incubated with DS-96 for an hour before addition to cell monolayer. This was to 
allow sufficient time for the interaction to take place between DS-96 and the target 
molecule, chlamydial LOS, prior to exposure of EBs to the host cell. Exposure of 
infectious EBs to concentration of DS-96 greater than 1 µM resulted in inhibition of 
chlamydial growth as indicated by a decrease in the percentage of the host cells 
containing inclusions after 24 h (Fig. 4.1B and C). Over a concentration range of 0-
16 µM, a dose-dependent inhibition of infection was observed with greater than 80% 
inhibition at 8 µM relative to DMSO mock-treated culture. More than a doubling in the 
number of infected cells was observed as DS-96 concentration was reduced from 8 to 
4 µM (83.9% and 31.3% inhibition, respectively). Interestingly, the size of individual 
inclusions after 4 µM DS-96 treatment appeared much smaller in comparison to those of 
DMSO mock-treated sample (Fig. 4.1B), although this was not quantified. This 
observation may be explained by the ability of multiple EBs to infect a single cell and 
form much larger inclusions, suggesting that fewer bacteria, on average, infected 
individual cells as a result of DS-96 treatment at 4 µM. In concert with this hypothesis, 
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inhibition levels observed between treatments with 2 and 4 µM of DS-96 are similar; 
however, the inclusions in 2 µM are larger and similar in size to DMSO treated samples. 
An alternative hypothesis is that DS-96 is slowing Chlamydia entry and/or developmental 
progression (e.g. replication), resulting in smaller inclusions at certain concentrations. 
As Chlamydia is an obligate intracellular organism, it is crucial to ensure that the 
observed inhibitory effect is due to the direct action of the compound on Chlamydia 
rather than an indirect cytotoxic effect on the host cell. Although no detectable toxicity 
was reported in the murine model [198], DS-96 has not been reported previously in cell 
culture. To evaluate the possible cytotoxicity of DS-96, a resazurin-based assay 
(alamarBlue) was used to quantitatively assess host cell metabolic activity following 
exposure to DS-96 (Fig. 4.2). This assay indicated that no significant cytotoxicity was 
observed following exposure of DS-96 concentrations up to 8 µM. At 16 µM, the 
reducing capability of the host cell decreased to approximately 60% of the untreated 
cells, which is consistent with host cell rounding evident at 16 µM treatment by 
microscopy (Fig. 4.1B). Based on the inhibitory effect and absence of cytotoxicity at 8 
µM, this concentration was used for subsequent studies. 
 
DS-96 blocks the early events of the chlamydial developmental cycle  
To better understand the underlying inhibitory mechanism of DS-96, infected 
samples were treated with DS-96 at different time periods during the developmental cycle 
and Chlamydia growth was examined. When infected cells were treated with DS-96 after 
bacteria were allowed to bind and begin entering host cells, no significant effect on the 
bacterial growth was observed (Fig. 4.3). This suggests a possibility that DS-96 is 
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Fig. 4.2. AlamarBlue cytotoxicity assay. Cytotoxic effect of DS-96 was examined 
using a redox indicator alamarBlue. Host cells were incubated with various 
concentrations of DS-96 for 2 h and metabolic activity of the host cells was measured 
after 24 h using spectrophotometric readings at 570 nm and 600 nm. 
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Fig. 4.3. Comparison of Chlamydia infection levels following various DS-96 pre-
incubation conditions. Infection levels were compared among the samples treated 
with DS-96 in various treatment conditions during the developmental cycle. Percent 
inhibition of infection level in the presence of DS-96 relative to DMSO treatment was 
quantified using the automated image-based method. Error bars indicate standard 
deviation of the triplicate samples.  
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membrane impermeable, and consequently, does not have access to the bacteria once they 
are internalized into host cells. It could also indicate that LOS is not essential once 
Chlamydia has gained access to the cell and begun replicating. Therefore, the effect of 
DS-96 treatment prior to the internalization of EBs was examined further (Fig. 4.4). The 
treatment conditions included pre-treatment of EBs for an hour prior to addition to host 
cells, co-incubation of DS-96 and EBs with the host cell, and addition of the compound 
after EBs were allowed to incubate with host cells (Fig. 4.4A). As Chlamydia relies on 
the host cell for survival and replication, it was also important to ensure that DS-96 
exposure to the host cell does not perturb the cell and indirectly affect Chlamydia 
infectious processes. Therefore, the host cells were pre-treated with DS-96 for an hour 
prior to incubation with the bacteria. As expected, the compound was most effective in 
inhibiting Chlamydia infection when the bacteria were pre-treated prior to infection 
(95.5%, Fig. 4.4B). When DS-96 and the bacteria were simultaneously added to the cells 
(co-incubation), the level of inhibition was decreased to 55.4%, indicating that the 
compound requires sufficient time to establish an interaction with its target. When 
compound was added after EBs had incubated with host cells for 2 h, DS-96 exhibited no 
inhibitory effect on Chlamydia growth, supporting the earlier observation that the 
compound may be unable to cross the eukaryotic cell membrane. Pre-treatment of host 
cells prior to infection resulted in only a minimum level of inhibition (8.6%). Together, 
these observations support that DS-96 blocks Chlamydia infection during the early stages 
of the developmental cycle, specifically prior to chlamydial entry into the host cell. 
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Fig. 4.4. DS-96 inhibits initial stages of Chlamydia infection through interaction 
with EBs rather than host cell. Infection levels were compared among various 
treatment conditions of DS-96 (8 µM). (A) Treatment conditions; a. pre-treatment of 
bacteria, b. co-incubation of bacteria and host cell, c. addition of DS-96 to the infected 
culture 0-2 hpi, d. pre-treatment of the host cell. (B) Inhibition of inclusion formation 
relative to mock-treated samples was quantified for each treatment condition 24 hpi 
using the automated image-based method (32). Percentage of infection was calculated 
based on the number of inclusion positive cells in DS-96 treated samples relative to 
DMSO treated samples. Error bars indicate standard deviation of triplicate samples.  
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DS-96 treatment impairs Chlamydia attachment and entry 
To determine more specifically which steps of the developmental cycle were 
blocked by DS-96, attachment of Chlamydia to the host cell was examined. 
C. trachomatis EBs were pre-treated with DS-96 for an hour prior to infection, and then 
given sufficient time (1h) to adhere to L929 cells at 4 °C. After inoculum was removed 
and cells were washed to remove the unbound bacteria, adherence of EBs was 
qualitatively examined by immunofluorescent microscopy (Fig. 4.5). Heparan sulfate, as 
a highly negatively charged polysaccharide, is known to block Chlamydia adhesion to the 
target cell in vitro by charge repulsion [105, 108, 110, 112, 224], and served as a positive 
control for an inhibitor of Chlamydia adhesion in this study. In the untreated sample 
(DMSO), an average of 15 to 20 EBs appeared to be associated with the host cell surface 
(Fig. 4.5, DMSO). As expected, the bacterial adhesion was blocked when EBs were pre-
treated with heparan sulfate prior to infection (Fig. 4.5, Heparan sulfate). In samples pre-
treated with DS-96, inhibition was observed as indicated by a decrease in the number of 
EBs associated with host cell. However, unlike heparan sulfate, DS-96 treatment did not 
result in complete prevention of bacterial adhesion, and rather, the treatment decreased 
the number of bacteria bound to a single cell by approximately with 70%, with 2 to 5 EBs 
per cell remained bound to the cell surface (Fig. 4.5, DS-96). This observation was 
striking given that 8 µM of DS-96 consistently resulted in high level of inhibition (greater 
than 85%) of inclusion formation throughout our study (Fig. 4.1C, 4.3, 4.4). This result 
indicated that the majority of EBs that remained bound to the host cell in the presence of 
the compound was still unable to form productive inclusions.  
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Fig. 4.5. DS-96 blocks attachment of C. trachomatis EBs host cell surface. L929 
cells were incubated with highly purified EBs pre-treated with DS-96 (8 µM), heparan 
sulfate, or mock-treated (DMSO) for an hour at 4 °C. Infected cultures were 
thoroughly washed to remove unbound bacteria, fixed with methanol, and 
immunofluorescently stained.  
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One possible explanation for this observation is that DS-96 blocked 
post-attachment events, in addition to the bacterial adhesion. To investigate this 
possibility, entry of Chlamydia into the host cell was examined. Similar to the attachment 
assay, EBs pre-treated with DS-96 or mock-treated (DMSO) were allowed sufficient time 
(4h) to attach and enter the host cell. Differential immunofluorescent staining was 
performed to discriminate between the internalized bacteria and those that remained on 
the surface of the host cell, and the samples were assessed by confocal microscopy (Fig. 
4.6A). Two subsequent staining steps were performed before and after permeabilization 
of the host cell membrane to achieve labeling of the extracellular bacteria with red 
fluorophore and total bacteria with green fluorophore. In the representative images shown 
in Fig. 4.6A, the majority of EBs in mock-treated sample appeared in green, indicating 
that these EBs had been internalized. When pre-treated with DS-96, consistent with the 
observation in the attachment assay, bacterial adhesion was significantly decreased as 
indicated by a decrease in the number of total EBs associated with the host cell. In 
contrast to mock-treated sample, EBs associated with the host cell in DS-96 treated 
samples were co-stained and appeared in yellow, indicating that these EBs remained 
extracellular. Quantification of the number of the extracellular and total EBs reveled that 
pre-treatment of the bacteria with DS-96 resulted in a drastic decrease in the percentage 
of internalized EBs from 86.3% in mock-treated sample to 2.6% in DS-96 treated sample 
(Fig. 4.6B). These findings demonstrate that DS-96 blocks entry of C. trachomatis into 
host cells, in addition to adherence.   
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Fig. 4.6. Entry of C. trachomatis EBs into the host cell is inhibited by DS-96. 
C. trachomatis EBs were allowed to attach and enter host cells. Differential 
immunofluorescent staining was performed 4 hpi to discriminate between the 
extracellular and internalized EBs. (A) Representative images of infected cells. Host 
cell surface-associated EBs were labeled with anti-MOMP antibody (red) prior to cell 
permeabilization, and total EBs (intracellular + extracellular) were labeled with anti-
Chlamydia antibody (green) after permeabilization. The inset shows the internalized 
bacteria (green) in mock-treated sample and the extracellular bacteria (yellow) in DS-
96 treated sample. (B) Percent of EBs internalized relative to total EBs was quantified.    
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The effect of DS-96 on centrifugation-assisted infection 
Since the first report by Weiss and Dressler [225], it has been long known that 
centrifugation of the chlamydial inoculum onto host cell monolayers enhances infectivity, 
although the degree of enhancement varies among different species and serovars. The 
means by which centrifugation enhances Chlamydia infectivity are not fully understood; 
however, centrifugation is thought to override binding and entry mechanisms and greatly 
enhance absorption of the bacteria [224]. Interestingly, it has been reported that the 
inhibitory effect of neutralizing antibody and heparan sulfate against Chlamydia is 
overcome by centrifugation [226]. To examine whether DS-96 was merely inhibiting 
binding and entry or also having further effect, such as inactivation of EBs, the inhibition 
assay was performed with static and centrifugation-assisted infection (Fig. 4.7). In the 
presence of heparan sulfate, static infection resulted in 92.9% inhibition in Chlamydia 
growth. However, this inhibition was overcome when inoculation was facilitated by 
centrifugation (900 x g for 1 h). In comparison, when C. trachomatis EBs were treated 
with DS-96, a high level of inhibition (95.3%) was maintained through centrifugation-
assisted infection. Further studies are needed to determine what post-entry event(s) is 
perturbed by DS-96, or if infectious EBs are inactivated after exposure to the compound. 
Nevertheless, it is of interest to note that the bacteria are unable to progress through the 
developmental cycle even when the absorption is facilitated by centrifugation.  
While C. trachomatis LGV biovar strains can efficiently infect cultured 
mammalian cells, non-LGV strains generally require centrifugation for efficient infection 
in cell culture. LGV serovar L2 is a commonly used C. trachomatis laboratory strain due 
to relative ease of cultivation and shorter developmental cycle. However, trachoma 
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Fig. 4.7. Inhibition by DS-96 is maintained after centrifugation. Following pre-
treatment of EBs with DS-96 (8 µM) or heparan sulfate (HS) for 1 h, infection was 
performed with or without centrifugation (900 x g for 1 h). Infected cultures were 
fixed with methanol, immunofluorescently stained, and analyzed for inhibition of 
inclusion formation 24 hpi using the image-based automated assay. Error bars indicate 
standard deviation of the mean of triplicate samples.  
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 serovars D, E, and F are more clinically relevant strains since they are reported to be the 
most prevalent urogenital serovars worldwide [227]. With the data revealing that the 
effect of DS-96 is maintained through centrifugation-assisted inoculation, an inhibition 
experiment was performed with C. trachomatis serovar D and the mouse pathogen 
C. muridarum, both of which are typically infected using the centrifugation-assisted 
procedure. Greater than 80% inhibition of the bacterial growth was observed for both 
C. trachomatis serovar D and C. muridarum at 4 µM, a concentration lower than needed 
for equivalent inhibition of C. trachomatis LGV strain (Fig. 4.8).  
 
Treatment of EBs by DS-96 alters the binding of antibody against Chlamydia LOS 
Considering the rational design of the compound, along with the structural 
similarities between E. coli and Chlamydia lipid A, it is highly anticipated that the 
observed inhibitory effect of DS-96 in Chlamydia infection is through the interaction 
with LOS. In an attempt to demonstrate this interaction, the immunofluorescent staining 
pattern of the bacteria by monoclonal antibody specific to chlamydial LOS was examined 
by immunofluorescence microscopy (Fig. 4.9). It was anticipated that binding of DS-96 
to LOS could possibly alter the antibody-binding epitope on LOS, and consequently 
results in the absence of LOS staining. To perform this study, purified C. trachomatis 
EBs were pre-treated with DS-96 or mock-treated with DMSO for control, and allowed to 
adhere to the plastic bottom of a cell culture plate for an hour. Following methanol 
fixation, samples were stained with monoclonal antibody against LOS or MOMP for 
control, and counterstained with DAPI. When visualized by immunofluorescence 
microscopy, anti-MOMP antibody stained the bacteria similarly to DAPI staining in both 
 129 
  
Fig. 4.8. Inhibition of C. trachomatis serovar D and C. muridarum. Centrifugation-
assisted infection was performed with C. trachomatis serovar D (A) and C. muridarum 
(B) in the presence of various concentrations of DS-96, and quantified 24 hpi using 
automated enumeration method. Percent inhibition was counted based on the number 
of inclusion positive cells in DS-96 treated samples relative to DMSO treated samples. 
Error bars indicate standard deviation of the triplicate samples.  
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Fig. 4.9. Pre-treatment of EBs with DS-96 results in reduction of anti-LOS 
staining. Purified EBs were treated with DS-96 (8 µM) or DMSO and stained for 
MOMP (A) or LOS (B) following methanol fixation. Samples were counterstained 
with DAPI to visualize the total number of bacteria. 
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control and DS-96 treated samples. In contrast, while anti-LOS staining was consistent 
with DAPI staining in the control sample, staining by anti-LOS was completely absent in 
the sample treated with DS-96. Although this does not provide a direct evidence for an 
interaction of DS-96 with LOS, it suggests that DS-96 treatment of Chlamydia results in 
altering or possibly masking the epitope recognized by the anti-LOS antibody used in this 
study.   
 
The effect of phosphate on the activity of DS-96 
HBSS is a common buffer in Chlamydia infection in cell culture, and was used 
throughout this study. However, sucrose-phosphate-glutamate (SPG) has been generally 
accepted as a suitable transport and storage medium for Chlamydia. More importantly, it 
is commonly used in animal challenge studies. Before considering challenge studies in an 
animal model, the inhibition study was repeated using SPG in place of HBSS. 
Surprisingly, a complete lack of inhibition by DS-96 (8 µM) was observed when the cell 
culture inhibition assay was repeated with SPG (data not shown). To determine which 
component of SPG (220 mM sucrose, 8.5 mM Na2HPO4, 3.7 mM KH2PO4, 4.9 mM L-
glutamic acid) was accountable for the impairment of DS-96 activity against Chlamydia, 
each constituent was added separately to HBSS, and the effect on DS-96 activity was 
observed in the cell culture infection (Fig. 4.10). In the presence of sucrose or glutamic 
acid, the inhibitory activity of DS-96 remained comparable to the control (HBSS alone), 
resulting in a high level of inhibition. In contrast, when Na2HPO4 and KH2PO4 were 
added together to HBSS, the level of infection was similar to the untreated sample, 
indicating that the activity of DS-96 against Chlamydia infection was impaired in the  
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Fig. 4.10. Phosphate impairs activity of DS-96. Inhibition assay was performed 
with HBSS. Inhibition assay was performed with HBSS supplementing with each 
constituent of SPG. Samples were fixed with methanol 24 hpi. Chlamydia was stained 
with anti-MOMP antibody (green) and host cells were counterstained with DAPI 
(nuclei, blue) and Evan’s Blue (cytoplasm, red).  
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presence of these components. Considering that the molecular interaction of DS-96 and 
E. coli LPS is expected to involve formation of salt bridges between the two phosphates 
on lipid A and the amine groups on DS-96 [198, 215], it is reasonable to speculate that 
free phosphate from Na2HPO4 and KH2PO4 competitively interact with the amine for the 
salt bridge formation essential for the activity of DS-96. Although phosphate is 
commonly used in buffer solutions and present in also HBSS, the concentration of 
phosphate is approximately 15 times higher in SPG than in HBSS, which suggests the 
possibility that phosphate component of the buffer, at high concentration, outcompetes 
lipid A for the interaction with DS-96. To assist in supporting this possibility, the 
experiment was repeated using PBS, which contains the phosphate concentration 
comparable to SPG. The data revealed that PBS blocked the activity of DS-96 similarly 
to SPG, supporting that phosphate is the responsible component in impairment of the 
activity of DS-96. Importantly, this observation gives further evidence that DS-96 is 
indeed interacting with Chlamydia lipid A in a similar manner to its interaction with E. 
coli lipid A. 
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Discussion 
In search for an active component effective against Chlamydia infection with 
potential to be considered for a vaginally delivered microbicide, the LPS binding 
molecule, DS-96, was examined for inhibitory properties. Numerous observations within 
this study support that DS-96 inhibits Chlamydia infection of cell culture. A dose 
dependent inhibition was observed with greater than 80% protection at 8 µM (Fig. 4.1B 
and C). Attachment to the host cell appears to be the stage of infection where EBs were 
predominantly inhibited by DS-96 treatment (Fig. 4.5), although entry and possibly post-
entry events were also affected by the treatment (Fig. 4.6 and 4.7). The possible effect on 
post-entry events is highlighted by the inhibition observed following centrifugation-
assisted infection, which is thought to override binding and entry mechanisms. This study 
also provided indirect evidence for the specificity of DS-96 interaction with Chlamydia 
LOS, which was demonstrated by the absence of immunofluorescence detection of LOS 
following DS-96 treatment (Fig. 4.9), as well as the effect of high phosphate 
concentration on DS-96 activity (Fig. 4.10), which is discussed in further depth below. 
Together, these data support that DS-96 is an effective inhibitor of Chlamydia infection, 
albeit within tissue culture cells.  
In addition to the commonly used laboratory strain C. trachomatis LGV, we 
tested the activity of DS-96 against C. trachomatis serovar D and C. muridarum (Fig. 
4.8), as one of the most clinically prevalent serovars [228-230] and a mouse pathogen, 
respectively. Interestingly, lower doses of DS-96 were equally effective against these 
strains as compared to LGV, indicating higher susceptibility. Although further studies 
will be required to provide more evidence, these observations may suggest a possibility 
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that serovar D and C. muridarum have greater requirement for LOS in their infectivity 
compared to serovar LGV. Considering that the structure of lipid A glucosamine 
backbone is well conserved throughout Gram-negative bacteria [231], it is highly 
unlikely that the affinity of DS-96 towards lipid A varies among Chlamydia spp. 
However, the requirements for LOS in the establishment of productive infection may be 
different between various serovars and species of Chlamydia due to the difference in their 
tissue tropism. The idea of differential requirements for infectivity between serovars and 
various species of Chlamydia is well accepted, especially for the specific ligand-receptor 
interactions during the bacterial attachment and entry [221].  In support of our findings, it 
has been reported that C. trachomatis serovar E was more susceptible to various LOS 
inhibitors than serovar LGV in vitro [152]. 
DS-96 served in this study as a chemical biology tool to examine a role for LOS 
in Chlamydia biology. Despite the recent major advances in genetic systems [232-237], 
routine genetic manipulation of Chlamydia with classic techniques remains challenging. 
The use of inhibitors targeting specific virulence factors can substitute to facilitate the 
studies of this nature. Our data demonstrated that both attachment and entry processes 
of C. trachomatis were impaired in the presence of DS-96, which may reflect a possible 
role of LOS in the early events during the developmental cycle, specifically binding and 
entry. Other studies have used Chlamydia LOS as a target for disruption of the 
developmental cycle, and various functions have been proposed [151, 152]. Fadel and 
Eley postulated a possible general role of LOS in Chlamydia infectivity [152]. They 
demonstrated that infection of human epithelial cells by C. trachomatis serovar LGV and 
serovar E was inhibited in the presence of purified LOS, PMB, antibody 
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against C. trachomatis LOS, and synthetic Kdo [152]. Similar to our study, a role of 
Chlamydia LOS in adherence was also suggested [152]. More recently, Nguyen et al. 
examined the biological significance of Chlamydia LOS using LOS biosynthesis 
inhibitors (LpxC inhibitors) and proposed a crucial role of LOS in proper morphological 
transition of RBs to EBs [151]. Their study revealed that a decrease in the number of 
progeny EBs was generated in the presence of LpxC inhibitors [151]. They also reported 
that OmcB, a membrane protein specific to EB surface, was poorly expressed in the 
absence of LOS [151]. Our study extended the possible role of LOS to chlamydial 
attachment and entry steps, although the inhibitory effect may be indirect. Similar to the 
effect of LpxC inhibitors on the expression of OmcB, the interaction between DS-96 and 
LOS may be disrupting other key surface molecules required for binding and entry. For 
instance, Chlamydia is known to promote entry into host cells by inducing host cell actin 
polymerization via injection of T3S effector, Tarp [238, 239]. Considering the findings 
by Nguyen et al., it is possible that DS-96 treatment of LOS results in functional 
disruptions of other outer membrane surface molecules such as T3SS.  
One of the unexpected, but potentially revealing observations of this study was 
the blocking of DS-96 inhibitory effect by high phosphate concentrations. With an 
expectation to examine the efficacy of DS-96 in vivo in the near future, the inhibition 
experiments were repeated with SPG, a buffer commonly used in animal challenge 
model. To our surprise, the inhibitory effect by DS-96 was reversed in the presence of 
SPG (data not shown), and it was determined that phosphate was solely responsible for 
blocking the inhibitory activity of DS-96 (Fig. 4.10). The observation was further 
confirmed when PBS, a buffer containing phosphate at a concentration similar to SPG, 
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also blocked DS-96 activity. This observation was particularly intriguing considering the 
molecular design of DS-96. Sil et al. reported the central pharmacophore, which has been 
experimentally tested and defined for optimal recognition and neutralization of lipid A 
[198, 240]. These pharmacophore properties include: (i) two protonatable cationic 
functions ≈14 Å apart are necessary for simultaneous ionic interactions with the 
negatively charged phosphates on lipid A (ii) appropriately positioned hydrophobic 
groups. Given that the ionic interaction with the phosphates on lipid A is a requisite for 
the compound activity, it is plausible to reason that deactivation of DS-96 is a result of 
the free phosphate in the buffer solution competitively binding to the amine groups on 
DS-96. This observation, albeit indirectly, supports the specificity of the interaction 
between DS-96 and Chlamydia lipid A. Furthermore, with the ultimate goal of 
developing vaginally delivered microbicide, formulation is a critical factor to be 
considered for the stability of the compound under the vaginal environment, where 
various factors may influence the activity of the compound. Deactivation of DS-96 by 
phosphate observed in this assay emphasizes the importance of compound formulation. 
Nonetheless, considering the effectiveness against C. trachomatis infection in vitro along 
with the demonstrated low toxicity in a mouse model, it is expected that DS-96 will 
performed well as a microbicide candidate compound in future animal model studies. 
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Chapter V.  
Discussion 
  
In the effort to develop a vaginally-delivered microbicide for prevention of genital 
C. trachomatis infections, our first task was to addressed the lack of effective method for 
rapid enumeration of Chlamydia in cell culture, which has greatly hampered the 
possibility for large-scale in vitro studies of the organism, including identification of anti-
Chlamydia agents. Successful development of the automated image-based method 
enabled us to evaluate the susceptibility of Chlamydia to microbicide candidates 
throughout this work in a relatively large-scale assay, and is expected to make an 
important contribution to the Chlamydia research field by providing a powerful analysis 
tool.  
As further described below, LOS was rationally selected as a molecular target for 
prevention of C. trachomatis infection in our study as a Gram-negative specific molecule 
that predominates on chlamydial surface. Whereas LOS is not generally considered 
important as a protective antigen in C. trachomatis infections for the purpose of vaccine 
[241, 242], our study demonstrated that targeting chlamydial LOS by a small molecule is 
highly effective in blocking infection prior to the bacterial entry in vitro, and therefore, 
has a high potential to be a suitable approach for prevention of Chlamydia infection. In 
addition, utilizing DS-96 as a molecular probe, our study revealed the possible role of 
chlamydial LOS in the bacterial attachment and entry steps, and expanded upon the 
current understanding of the biological significance of chlamydial LOS.  
 
 142 
Utility of the automated assays developed  
The automated image-based analysis method developed in our study significantly 
improved the efficiency of fluorescence microscopy analysis of Chlamydia infection in 
cell culture, for which the traditional method is manual and not amenable to a large-scale 
assay. This method was successfully utilized throughout the studies described in Chapter 
III and Chapter IV, as well as in recently published reports [155, 237]. The use of this 
assay, however, is not limited in application for simple quantification of chlamydial 
inclusions. With fluorescent labeling of various molecules of interest, along with minor 
modifications to CellProfiler pipeline, this method offers a powerful tool for a wide 
variety of Chlamydia research that currently relies on manual analysis of fluorescence 
microscopy images. For instance, the method was used in a recently published study to 
measure inclusion size [237]. Quantification of inclusion size allows us to observe subtle 
alterations due to delayed or halted developmental cycle, which is beyond the simple 
presence or absence of inclusion. Whereas a simple binary classification of infected and 
uninfected host cells was used in our study, minor modifications to the pipeline within 
CellProfiler would allow classification of analytic subjects into more than two classes for 
identification of complex and subtle phenotypes. For example, translocation of 
chlamydial proteins into host cell cytosol (e.g. T3S effector proteins,), recruitment of host 
cell proteins to chlamydial inclusion (e.g. GTPase, lipid transferase), Chlamydia-induced 
modification of host cell processes (e.g. actin remodeling, Golgi fragmentation), or other 
subcellular localization of host or chlamydial proteins can be analyzed in large-scale. In 
addition, the recent advent of a method for transformation of Chlamydia enabling the 
development of essential molecular tools [232] is likely to extend application of this 
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image-based method in studies utilizing transformed Chlamydia expressing fluorescent 
proteins of interest.  
While the image-based method developed in our study offers a tool for the 
detailed studies of in vitro Chlamydia infection, our adaptation of alamarBlue assay is 
perhaps more amenable to a true high-throughput format anti-Chlamydia compound 
screening, owing to the reduced liquid-handling requirements, cost-effectiveness, and the 
overall hands-on time involved in the assay. Additionally, a high-throughput drug 
screening process often requires a separate counter-screen to eliminate cytotoxic 
compounds [243]. AlamarBlue assay detects a decrease of host cell viability regardless of 
the underlying mechanisms, which can be either progression of Chlamydia infection in 
the absence of anti-Chlamydia activity, or cytotoxicity of compounds. And therefore, 
alamarBlue-based assay serves dual functions in screening of inhibitory compounds. A 
large-scale anti-Chlamydia compound screening using the alamarBlue-based automated 
assay has been initiated in our laboratory in collaboration with the University of Kansas 
High-Throughput Screening (KU HTS) facility [244, 245]. Automation of liquid transfer, 
including plating of eukaryotic host cells and Chlamydia infection, is also in progress and 
expected to enable high-throughput screening of anti-Chlamydia compounds in a fully 
automated fashion.  
 
Limitations of Cell Culture Model for studies of Chlamydia  
In this study, identification of anti-Chlamydia compounds and elucidation of 
biological function of chlamydial LOS were performed based on microscopic 
observations of infected cell culture. Largely due to the obligate intracellular nature of the 
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organism, Chlamydia research heavily relies on cell culture model. As reviewed in 
Chapter I, various and sometimes conflicting studies have been reported regarding the 
host cell receptors and chlamydial ligands involved in attachment and entry processes. A 
possible explanation for the discrepancy among various studies on the interaction of 
Chlamydia with the host cell may partially be due to the limitations of cell culture 
models.  
Cell lines commonly used for infection of Chlamydia include McCoy and L929 
fibroblast lines, both of which C. trachomatis may not infect in vivo [246, 247], or HeLa 
cells, human papilloma virus-transformed cervical epithelial cells. During natural 
infection, C. trachomatis urogenital serovars predominantly infect the polarized epithelial 
cells lining the reproductive tract. These polarized cells are quite different in organization 
compared to non-polarized cell culture lines mentioned above. The plasma membrane of 
polarized epithelial cells is divided into apical and basolateral domains, which are 
biochemically and physiologically unique, and characterized by markedly different 
protein and lipid compositions as well as distinct receptors [248, 249]. The inability for 
clinically relevant strains of C. trachomatis to achieve adequate infectivity in vitro 
without the aid of centrifugation may suggest that the tissue culture cells lack host cell 
receptors or other factors utilized by Chlamydia in natural infection. Supporting this idea, 
numerous studies have reported intriguing differences in in vitro Chlamydia infections of 
polarized versus non-polarized cells, including infectivity, mechanisms of entry, the 
duration and synchronization of the developmental cycle, persistent state, innate 
inflammatory response, and antibiotic susceptibility [250].  
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The pH of the culture is another key parameter to be considered in cell culture 
system as it influences both chemical and biological properties within the cell culture. For 
instance, the culture pH can influence the surface charge of Chlamydia and the host cells, 
which are involved in the electrostatic interaction mediating the initial association of the 
bacteria and the host cell. While the pH of cell culture medium is typically around 7, the 
vaginal pH of healthy women typically ranges 3.6 to 5.0 [251]. A study reported the 
effect of pH on in vitro anti-Chlamydia activity of cellulose-ether polymers, where the 
inhibitory effect was polymer concentration-dependent at pH 5, and inversely 
concentration-dependent at pH 7 [211]. Our attempt in testing microbicide candidates at 
lower pH, however, was unsuccessful due to obvious adverse effects observed in host 
cells in buffer mimicking vaginal pH, which is considerably lower than the pH used 
typically for L929 cells (i.e. around pH 7). Together, these observations highlight the 
limitations of studies in cell culture model and importance of translating the basic 
observations from cell culture system into a more natural context such as a small animal 
model.  
 
Potential Roles of Chlamydia Lipooligosaccharide  
While numerous studies have been reported on the antigenic and immunogenic 
properties of Chlamydia LOS, the knowledge concerning the biological functions of LOS 
in viability or the pathogenesis of Chlamydia is surprisingly limited. As with all 
Gram-negative bacteria, LOS is a major component of the outer leaflet of chlamydial 
outer membrane [252]. The inner leaflet of the outer membrane and both leaflets of the 
inner membrane are made up with phospholipids, which are either synthesized by 
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Chlamydia or acquired and modified from host cell sources [253]. Interestingly, it has 
been reported that Chlamydia tolerates alteration of the final phospholipid composition 
and remain viable [253]. In contrast, C. trachomatis contains all of the genes necessary 
for de novo synthesis of LOS [254], suggesting the vital roles of LOS in Chlamydia 
pathogenesis and viability.   
Using DS-96 targeting lipid A as a chemical probe, we examined inhibition of 
Chlamydia growth at specific stages during the developmental cycle. We demonstrated 
that ability of EBs to attach and enter the host cell was greatly impaired in the presence of 
DS-96 (Fig. 4.5 and 4.6), and proposed that Chlamydia LOS plays an important role in 
these processes. The scope of this study, however, did not extend to exploring the 
mechanisms as to how LOS may be involved in these key steps of Chlamydia 
pathogenesis. And therefore, we cannot eliminate the possibility that LOS may not be the 
chlamydial component directly involved in the interaction with the host cell surface, and 
rather plays an indirect role by providing structural support for other molecules that are 
critical in these processes. A study has been reported to show that treatment of 
C. trachomatis EB with cross-linking agent disuccinimidyl selenodipropionate (SSP) 
resulted in cross-linking of LOS and MOMP [255], indicating the close association of 
LOS with MOMP on the surface of EBs. Considering the high abundance of LOS and 
MOMP on the surface of Chlamydia, it is reasonable to speculate that when bound by 
DS-96, LOS, either alone or with its association with MOMP, interferes with chlamydial 
protein/structure that plays a direct role in attachment and entry. The evidence for the role 
of MOMP in adherence of C. trachomatis has been presented by several studies [107, 
256, 257]. 
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It is also possible that binding of DS-96 to lipid A of LOS results in a compromise 
of the chlamydial surface, such as loss of the outer membrane integrity, rather than 
disruption of specific ligand-receptor interaction. Perhaps supporting this possibility is 
the observation that inhibition by DS-96 was maintained through centrifugation-assisted 
infections (Fig. 4.7), where it was concluded that EBs may have been “inactivated” by 
DS-96. If this “inactivation” was a reflection of the outer membrane disruption, an 
alteration of the outer membrane morphology would be expected. We performed 
scanning electron microscopy (SEM) to examine the effect of DS-96 on the surface 
morphology of EBs. This preliminary study did not show an apparent alteration of EB 
surface by the treatment; however, the lack of observable effects does not eliminate the 
above possibility, since effects could be too subtle for visualization by SEM.  
While our study primarily focused on the function of chlamydial LOS in the 
infectious EB form, LOS is shown to be present in both EBs and RBs. The differences in 
the exposure and arrangement of LOS between the surface of EBs and RBs have been 
reported by several studies [255, 258-260], suggesting distinct roles LOS plays in these 
two forms of the organism. The conversion of EB to RB occurs approximately 2 to 8 hpi 
and replication continues until about 18 hpi for C. trachomatis L2. When DS-96 was 
added during 0-6 and 6-12 hpi to examine the effect of the compound during these stages 
of the developmental cycle, no inhibition of chlamydial growth was observed (Fig 4.3). 
However, since membrane permeability of DS-96 has not been determined, the absence 
of effect may be as a result of the inability of DS-96 to have access to the bacteria once 
they are internalized by the host cell.  
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Although our chemical biology approach was unable to address the role of LOS 
after chlamydial entry, a recent report by Nguyen et al. used inhibitors of the LOS 
biosynthesis pathway to characterize the function of LOS post-chlamydial entry. It was 
demonstrated that RBs were able to replicate normally, and no alteration in the 
ultrastructure of the outer and inner membrane of RBs was observed when LOS 
biosynthesis was inhibited. However, these RBs were unable to undergo morphological 
transition into EBs in the absence of LOS, suggesting that chlamydial LOS in RB is 
essential for proper formation of infectious EBs [151]. These observations revealed an 
intriguing function of chlamydia LOS in the non-infectious RBs. Their study, however, 
did not address the role of LOS in the infectious EBs since the inhibitors have no effect 
on pre-formed LOS, and progeny EBs were not formed in the absence of LOS 
biosynthesis. Therefore, our research effort provided valuable new insights into the role 
of LOS in infectious EBs.  
 
DS-96 as a novel anti-Chlamydia compound 
The need for continued discovery and development of novel anti-chlamydial 
agents is highlighted by the limitations of the current strategy for prevention and 
treatment of C. trachomatis infection. To date, a limited number of small molecule 
inhibitors has been identified for Chlamydia. Several studies have been reported on the 
identification of compounds targeting Chlamydia type III secretion system (T3SS), 
including small molecule inhibitors of Yersinia T3SS [261-264] and a peptide mimetic 
targeting protein interaction essential for T3SS [265]. Recently, Chlamydia serine 
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protease CtHtrA was found to inhibit the viability of Chlamydia both in cell culture and 
mouse model [266].  
For the purpose of vaginal microbicide, the candidate inhibitors must have the 
ability to specifically target vaginal pathogens while having no deleterious effect on the 
normal vaginal flora. Vaginal microbiota of healthy women is typically dominated by the 
hydrogen peroxide-producing Gram-positive Lactobacillus species that are essential in 
maintaining vaginal homeostasis and providing the natural defense against pathogenic 
organisms [267-269]. The activity of DS-96 against Gram-positive bacteria species has 
not been examined. However, considering that DS-96 is designed to specifically target 
lipid A, a virulence factor unique to Gram-negative bacteria, it is highly anticipated that 
DS-96 would not have a major adverse effect on the Lactobacillus-dominated normal 
vaginal microbiota.  
On the other hand, DS-96 is likely to have activity against another common 
pathogen of genital mucosa, Neisseria gonorrhoeae. Like Chlamydia, the Gram-negative 
N. gonorrhoeae possesses LOS. Whereas the terminal oligosaccharides of gonococcal 
LOS are known for their ability to undergo phase variation at high rate [270, 271], the 
glucosamine backbone of lipid A is conserved. Similar to our study, Neisseria LOS has 
been implicated in the adhesion and invasion of host epithelial cells [272]. Which 
component of gonococcal pathogenesis would be inhibited by DS-96 remains to be 
elucidated; however, it is reasonable to expect that DS-96 binds to gonococcal lipid A, 
which in turn inhibits Neisseria infection. Therefore, our future studies must include 
in vitro susceptibility studies of N. gonorrhoeae and Lactobacillus species to DS-96.  
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Another obvious future work would be to examine if in vitro inhibitory effects of 
DS-96 against Chlamydia infection would translate in vivo. In collaboration with Dr. Luis 
de la Maza (University of California, Irvine), investigation of DS-96 activity in a mouse 
challenge model has been initiated. Although no definitive conclusions could be made 
from the initial study due to the lack of statistically sufficient number of test animals 
involved, two out of five animals showed nearly complete protection when EBs were pre-
treated with DS-96 prior to injection into the mouse (data not shown). These animal 
challenges will be repeated with larger test groups to obtain statistically significant and 
reproducible results.  
While this study focused on the application of DS-96 as a candidate for 
microbicide, the application of DS-96 may not necessarily be limited to prevention. 
DS-96 may also be effective as a therapeutic by blocking spread of Chlamydia. A plaque 
assay can be performed to examine if cell-to-cell transmission of a single EB over several 
successive developmental cycles can be blocked in the presence of DS-96.   
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